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ABSTRACT 
 
 
Coordination chemistry of imidazole thione and selone compounds with 2nd and 3rd row  
d-block metals are of considerable interest due to their wide-ranging applications of 
reducing heavy metal toxicity, catalysis, and antimicrobial and antitumor activity. 
Antioxidant behavior of some imidazole thiones and selones is attributed to their ability to 
scavenge hydrogen peroxide or other reactive oxygen species as well as their coordination 
of redox-active iron and copper to prevent hydroxyl-radical-mediated DNA damage. 
Chapter 1 of this dissertation provides an overview of 2nd and 3rd row d-block metal 
complexes with imidazole thione and selone ligands and their applications. 
Ruthenium complexes with labile solvato ligands represent versatile synthons for entry 
into Ru(II) coordination chemistry. Thus, homoleptic and heteroleptic solvato Ru(II) 
complexes were synthesized from readily available RuCl3·xH2O (Chapter 2). An improved 
synthesis of [Ru(NCCH3)6][BF4]2 affords higher yields with fewer reaction steps, and the 
[Ru(NCCH3)2(DMSO)3Cl][BF4]1.5[Cl]0.5[Na], [Ru(NCCH3)4(DMSO)2][BF4]2, and 
[Ru(NCCH3)5(DMSO)][BF4]2, (DMSO = dimethylsulfoxide) mixed-solvato complexes 
could be useful for synthesizing heteroleptic Ru(II) complexes. 
Sulfur and selenium compounds can scavenge reactive oxygen species to prevent 
oxidative damage, and metal coordination can improve this activity. Therefore, novel 
homoleptic Ru(III) and Ru(II) complexes with methimazole (MMI), N,N’- 
dimethylimdiazole thione (dmit) and selone (dmise) ligands of the formula [RuL6]Cl3 and 
[RuL6][BF4]2 were synthesized (Chapter 3). Heteroleptic complexes RuL4Cl2 were also 
 iii 
synthesized with the same three ligands. The [RuL6]Cl3 complexes quickly react with 
hydrogen peroxide, with the MMI and dmise complexes reacting significantly faster than 
the dmit complex. [Ru(MMI)6]Cl3 also prevents iron-mediated DNA damage at very low 
micromolar concentrations. 
Ruthenium nitrosyl complexes are some of the most investigated compounds for 
biological NO delivery. Therefore, Ru(II)-nitrosyl complexes [Ru(NO)(L)4Cl][BF4]2 (L = 
dmit dmise) were synthesized from RuCl3·xH2O with silver nitrate as a simple and 
convenient nitrosyl source (Chapter 4). This novel method considerably simplifies 
synthesis of Ru-nitrosyl complexes with good yields and avoids the use of unstable or toxic 
starting materials to generate nitrosyl complexes. This work develops Ru(II) and Ru(III) 
chemistry as starting materials and with thione, selone, and nitrosyl ligands that have 
promising biological applications as antitumor, antimicrobial, and photodynamic therapy 
agents as well as catalytic applications. 
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CHAPTER ONE  
 
COORDINATION CHEMISTRY, BIOLOGICAL ACTIVITY, AND CATALYIC 
APPLICATIONS OF IMIDAZOLE THIONE AND SELONE COMPLEXES WITH 
SECOND- AND THIRD-ROW TRANSITION METAL IONS 
 
1.1. Biological roles of thione and selone compounds 
 Cysteine, selenocysteine, ergothioneine, and selenoneine are biological sulfur and 
selenium compounds (Figure 1.1) studied for their antioxidant properties. Cysteine and 
selenocysteine  amino acids play significant roles in protein structure and enzymatic 
activity.1-3 The main role of ergothioneine is protection against oxidative damage,4-11 and 
in vitro studies of selenoneine show it is a potent radical scavenger.12 Cysteine and 
selenocysteine contain thiol/selenol functional groups (C-SH/C-SeH), whereas 
ergothioneine and selenoneine contain thione/selone functional groups (C=S/C=Se). Thiol 
and selenol compounds have the ability to form disulfide13 and diselenide14 bonds that help 
to control cellular redox balance and play a significant role in enzymatic function. Similar 
to thiols, imidazole thiones can also form disulfide bonds upon oxidation.15 
H3N+ O
EH
O-
O-
O
N+
HHN
N
H
E
NN
R2R1
E
imidazole thione (E = S) or selon (E = Se)E= S; Cysteine
     Se; Selenocysteine
E= S; Ergothioneine
     Se: Selenoneine
 
Figure 1.1. Sulfur and selenium compounds discussed in this work (R = alkyl, aryl or H). 
  
 Ergothioneine and selenoneine are very effective radical scavengers, and their 
metal coordination abilities may also contribute to their biological functions.  
Ergothioneine scavenges reactive oxygen species (ROS), prevents copper-mediated 
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oxidative deoxyribose damage,16 and is proposed to bind iron to prevent iron-mediated 
oxidative damage.16 Selenoneine has not been studied for prevention of metal-mediated 
oxidative damage, but it effectively scavenges the 2,2-diphenyl-1-picrylhydroazyl (DPPH) 
radical, a radical commonly used to mimic biological radical species.12 Antioxidant 
activities of imidazole thione and selone compounds are attributed to binding redox-active 
iron and copper that represent essential biological elements17-19 to prevent hydroxyl radical 
generation and metal-mediated DNA damage, hydrogen peroxide scavenging, or 
scavenging other ROS.17-24 Brumaghim, et al.24 have examined the antioxidant activities of 
imidazole thiones and selones as antioxidants to prevent metal-mediated DNA damage in 
vitro. 
 The discovery of the antioxidant properties of ergothioneine4-11,16 and selenoneine12 
has prompted significant interest in the analogous thione and selone compounds for      
antithyroid,25-27 antioxidant,20,28 antimicrobial,29 and antifungal29 activities. In particular, 
methimazole (MMI; 2-mercapto-1-methylimidazole) is a widely prescribed antithyroid 
drug (Figure 1.2; R1 = CH3, R2 = H)25-26,30 that prevents oxidative DNA damage as a 
hydrogen peroxide scavenger.25-26  Similar imidazole thione and selone compounds have 
been synthesized with a wide variety of alkyl and aryl substituents (R1 and R2; Figure 
1.2).25-29 Many imidazole thione and selone compounds, including methimazole, also have 
been studied for their ability to coordinate a wide variety of metal ions.25-30   
 Imidazole thione and selone compounds have two resonance forms, neutral and 
zwitterionic, and the presence of a zwitterionic resonance structure increases their ability 
to bind metal ions by increasing the negative charge at the S or Se atom (Figure 1.3).20,31-32 
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The energetic contribution of this zwitterionic resonance structure for some imidazole 
chalcogenides has been examined by X-ray structural analysis of the C=E bond length      
(E= O, S, Se, Te), and the results of these studies show that the zwitterionic contribution 
 
Figure 1.2. Imidazole -thione and selone ligands discussed in this work. 
 
N N
R R'
E
N N
R R'
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Figure 1.3. Resonance structures of imidazole thione (E = S) and selone (E = Se) compounds (R, R’ = aryl, 
alkyl, or H).  
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increases with increasing atomic number of the chalcogenide.31 The C=O bond length is 
shorter than the thione and selone bond lengths, corresponding to a full double bond, thione 
and selone compounds have intermediate bond lengths, and the C-Te bond is nearly a 
single-bond length, indicating dominance of the zwitterionic resonance structure for the 
tellurium species.31 
 Imidazole thione and selone complexes of late first-row d-block metal ions have 
been extensively studied as described in a review by Stadelman, et al.20 Thione and selone 
coordination to second- and third-row d-block metal ions is also of significant interest, with 
applications for reducing toxicity of heavy metals,33-37 catalysis,38-42 and as      
antimicrobial43-45 and antitumor46-51 complexes. These wide ranging applications invite 
further exploration of the rich coordination chemistry of these systems; therefore, 2nd and 
3rd row d-block metal ion complexes with imidazole thione and selone ligands is the focus 
of this review. 
 
1.2. Coordination chemistry of imidazole thione and selone compounds   
 Imidazole thione and selone compounds coordinate a variety of metal ions, 
primarily through the S or Se atoms in monodentate fashion20 although in some cases, they 
can also bind as bidentate ligands through an unsubstituted N atom of the imidazole ring 
(Figure 1.4).52  The C=S/C=Se moiety of imidazole thione and selone compounds is 
electron rich as a result of the localization of negative charge on the S/Se atom due to 
resonance (Figure 1.).31,53 This, coupled with the large size and polarizable nature of the 
S/Se atom, gives these ligands soft Lewis basic properties. Since many of the 2nd and 3rd 
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row d-block metal ions are also soft Lewis acids, they form stable complexes with 
imidazole thione and selone ligands.54-59 
NHN
E
R
NN
E
R
M
MA B
 
Figure 1.4. A) Monodentate and B) bidentate binding modes of thione (E = S) and selone (E = Se) ligands, 
where M = metal and R = H, alkyl, or aryl group. 
 
 
 Imidazole thione complexes. Imidazole thione complexes are reported for all of the 
2nd row d-block metals in a variety of oxidation states: Y(III),57 Zr(IV),60-61 Nb(II),62 
Mo(0),63 Tc(V),64 Ru(II)/(III),38,65-66 Rh(II)/(III),65,69-70 Pd(II),53,65 and Ag(I),67 and Cd(II)77. 
Similarly, imidazole thione complexes of the 3rd row d-block metals include Hf(IV),60 
Ta(II),62 W(0),63 Re(IV),64 Os(II),66 Ir(III),69-70 Pt(II)/(III),50,53 Au(I/III),71-72 and Hg(II).55 
Complexes with imidazole selone ligands are less common, and are reported for late 2nd 
row d-block metal ions, including Ru(II)/(III),31 Rh(II)/(III),31,69 Pd(II),53,60 Ag(I),31 and 
Cd(II).68 Similar to 2nd row d-block complexes, imidazole selone complexes are only 
reported for the late 3rd row d-block metal ions Re(II),31 Os(II),31 Ir(0),31 Pt(II),48-49,53 
Au(III),53 and Hg(II).55 
 A wide variety of imidazole thione- and selone-containing ligands have been 
synthesized, but only a selection of the imidazole thione and selone ligands found in 2nd 
and 3rd row d-block metal complexes (Figure 1.2) are discussed in this review. The majority 
of these types of ligands are monodentate thiones or selones that bind through the sulfur or 
selenium atom. Bidentate ligands are typically synthesized by linking imidazole thione or 
selone moieties through alkyl, aryl, or borohydride groups.  Bidentate 
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benzoimithione/benzoimiselone ligands combine a thione/selone moiety with a thio- or 
selenoether group in a mixed functionality ligand (Figure 1.2).   
 Tridentate ligands can be mixed donor, such as the N,S,S-donor ligands bmtp, bptp, 
and  bbtp (Figure 1.2), where two N-substituted thione groups are linked through a pyridine 
bridge.69  In addition, three thione or selone groups can be linked through a borohydride 
moiety to yield ligands such as hydrotris(methimazolyl)borate (TmMe).65 These ligands are 
similar to the widely used hydrotris(pyrazolyl)borate (Tp) ligands, but replace the harder 
nitrogen atom donors with soft sulfur donors. In this review, complexes with similar 
imidazole thione and selone ligands are discussed based on the order of the metal ions in 
the periodic table. The complexes discussed do not represent all of the reported imidazole 
thione and selone complexes, but rather have been selected to highlight the variety of 
imidazole thione and selone complexes with 2nd and 3rd row d-block metal ions.  For the 
selected complexes, M-S/Se and C=S/C=Se bond lengths are presented and mostly 
compared to those of the unbound ligands, since these bond lengths are most diagnostic of 
the degree of electronic delocalization on the imidazole ring upon coordination             
(Figure 1.3). 
 Hydrotris(imidazole thione)borate ligands such as TmMe and its derivatives (TmEt, 
TmBu, and TmPh; Figure 1.2) have been used to synthesize complexes with the majority of 
the 2nd and 3rd  row d-block metal ions.60 The Zr(IV) and Hf(IV) complexes  
Cp(TmMe)ZrCl2 (Cp = cyclopentadienyl) and TmBuHf(CH2Ph)3 have been structurally 
characterized (Figure 1.5),61 and have Zr-S bond lengths in the range 2.66(11)-2.76(11) Å, 
in the middle of the range for most Cp-Zr-S complexes (2.46(11)-2.83(11) Å69).  The Hf-
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S bond length is 2.631(3) Å. The range of C=S bond lengths in these Zr complexes is 
1.71(4)- 1.73(4) Å, and for the Hf complex, the C=S bond length is 1.728(11) Å.  These 
values are approximately the same as the C=S bond length in unbound TmMe (1.69(4) Å).60 
The Nb(V) 
 
Figure 1.5. Molecular drawing from crystallographic data of A) Cp(TmMe)ZrCl2  and B) 
TmBuHf(CH2Ph)3.61 Hydrogen atoms are omitted for clarity. 
 
 
and Ta(V) complexes TmMeM(=NR)Cl2 (R = 2,6-iPr2C6H3; Figure 1.6)62 have Nb-S and 
Ta-S bond lengths of 2.5446(14) and 2.725(3) Å, respectively. Similar to the TmMe 
complexes of Zr(IV) and Hf(IV), C=S bond lengths for these Nb and Ta complexes are 
1.75(3) and 1.76(3) Å, respectively, relatively unchanged compared to unbound TmMe.62 
  Several homoleptic sandwich complexes of Ru(III), Rh(III), Pd(II) and Cd(II) with 
the tridentate (N-MeImid)TmMe (N-MeImid = N-methylimidazolium; Figure 1.2) thione 
ligand have been synthesized (Figure 1.7). The sandwich complexes [{κ3-(N-
MeImid)TmMe}2Ru]3+ and [{κ3-(N-MeImid)TmMe }2Rh]3+ have M-S bond lengths of 
2.374(4) and 2.453(10) Å, respectively, with C=S bond lengths of 1.720(4) and 
1.731(19)Å, respectively.65 Similarly, the structure of [κ2-(N≡C)TmMe )]2Pd65 (Figure 1.8) 
has a range of 2.333(11)-2.338(11) Å for the Pd-S bond lengths, with C=S bonds ranging 
from 1.721(4) to 1.725(5)Å.65 No significant differences in C=S bond lengths are observed 
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for the Ru(III) and Rh(III) complexes of κ3-(N-MeImid)TmMe and the Pd(II) complex of 
κ2-(N≡C)TmMe  compared to their respective unbound ligands. 
 
Figure 1.6. Molecular drawing from crystallographic data of A) TmMeNb(=NR)Cl2 and B) 
TmMeTa(=NR)Cl2.62 Hydrogen atoms are omitted for clarity. 
 
 
 
Figure 1.7. Molecular drawing from crystallographic data of A) [κ3-(N-MeImid)TmMe ]2Ru and B) [κ3-(N-
MeImid)TmMe ]2Rh.65  Hydrogen atoms, solvent, and counterions are omitted for clarity. 
 
 
 In general, ruthenium complexes are investigated for a wide range applications, 
especially in biology and catalysis, due to favorable ligand exchange rates, the range of 
accessible oxidation states (+2, +3, and +4), and ability of ruthenium ions to mimic iron,73 
In addition, ruthenium complexes are widely used as catalysts to catalyze very important 
reactions such as hydrogen transfer reaction, and organic polymerization.38     
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Figure 1.8. Molecular drawing from crystallographic data of [κ2-(N≡C)TmMe]2Pd.65 Hydrogen atoms are 
omitted for clarity. 
  
      The BmMe ligand, with a borohydride linking two imidazole thione groups (Figure 1.2), 
was used to synthesize fac-TmMeTc(CO)3 and fac-TmMeRe(CO)2(ImzH) (ImzH = 
imidazole; Figure 1.9).64 Similar Ru(II) and Os(II) complexes κ2-BmMeRu(CO)(PPh3)H 
and κ2-BmMeOs(CO)(PPh3)H also have been reported (Figure 1.10).66 In these complexes, 
Tc-S and Re-S bond lengths are 2.51(11) and 2.53(4) Å, respectively64 longer than the Ru-
S and Os-S bond lengths of 2.401(5) and 2.461(11) Å, respectively.66 In all of these 
complexes, there are no significant differences in the C=S bond lengths (1.70(2)-1.73(4) 
Å).64,66  
 
Figure 1.9. Molecular drawing from crystallographic data of A) fac-Tc(k2TmMe)(CO)3 and B) fac-
Re(TmMe)(CO)3.64  
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Figure 1.10. Molecular drawing from crystallographic data of A) κ2-BmMeRu(CO)(PPh3)H, and B) κ2-
BmMeOs(CO)(PPh3)H.66  
 
 Many complexes with monodentate imidazole thione ligands such as MMI, dmit, 
imdt, bimt, and himtAr and bidentate imidazole thione ligands such as tmeimt, mbit, ebit, 
and bismt (Figure 1.2) have been synthesized with most of the 2nd and 3rd row d-block 
metal ions. In an interesting ligand exchange reaction, treating Cp3Y with benzimidazole-
2-thiolate (bimt) forms the Y(III) complex (κ2-S,N-bimt)3Y(THF)2 (THF = 
tetrahydrofuran; Figure 1.11), where bmit protons are lost to the Cp ligands and 
deprotonated bimt binds as a bidentate ligand. In this complex, the Y-S bond length is 
2.996(6) Å, the longest of all the imidazole thione M-S bonds with 2nd row d-block metal 
ions. The Y-N bond length is 2.361(6) Å, and the C=S bond length is 1.706(5) Å, with    
C1-S1-Y1,  C8-S2-Y1, and C15-S3-Y1   angles of (κ2-S,N-bimt)3Y(THF)2  and 73.88(18), 
77.0(2), and 76.53(16)°, respectively,  and N1-Y1-S2 and N5-Y1-S2  angles of 91.5(2) and 
162.20(9)°, respectively.57  
      The tetramethylated imidazole thione, tmiemt (Figure 1.2), coordinates Mo(0) and 
W(0) to yield M(tmeimt)(CO)5 complexes (Figure 1.12). Mo-S and W-S bonds lengths are 
very similar at 2.610(11) and 2.614(14) Å, respectively, but the C=S bond lengths are 
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somewhat different at 1.719(2) and 1.731(5) Å, respectively.65 Both C=S bonds are longer 
than the C=S bond of unbound tmiemt (1.69(2) Å),65 and the longer C=S bonds in these 
low-valent Mo and W complexes suggest backbonding into the π* orbital of the C=S bond. 
 
Figure 1.11. Molecular drawing from crystallographic data of (κ2-S,N-bimt)3Y(THF)2.57 Hydrogen atoms 
are omitted for clarity. 
 
 
Figure 1.12. Molecular drawing from crystallographic data of A) [Mo(tmeimt)(CO)5 and B) 
W(tmeimt)(CO)5.63 Hydrogen atoms are omitted for clarity. 
 
  
 As can be inferred from the structures in Figure 1.2, thione ligands with aryl 
substituents are less common than those with alkyl substituents. An example of a Ru(II) 
complex bound to an N-aryl-imidazole-2-thione is cis-Ru(imt)2(PPh3)2Cl2 (Figure 1.13).57 
The structure of this complex has a Ru-S bond length of 2.478(1) Å,57 somewhat longer 
than  the Ru-S bond length in κ2-BmMeRu(CO)(PPh3)H (2.401(5) Å).66   
      A series of half-sandwich Rh(III) and Ir(III) complexes with bmtp, bbtp, and bptp 
ligands were synthesized by Jia, et al.,69 with representative structures of the 
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[CpM(bmtp)]Cl2 complexes shown in Figure 1.14. The range of Rh-S bond lengths is 
2.3829(12) to 2.3866(14) Å, not significantly different from Ir-S bond lengths that range 
from 2.3850(19) to 2.3870(16) Å.  The C=S bond lengths are little varied among different 
thione ligands and metal ions, with a range of 1.684(4)-1.687(4) Å for the Rh complexes 
and 1.696(5)-1.707(4) Å for the Ir complexes.69 
 
Figure 1.13. Molecular drawing from crystallographic data of cis-Ru(imtPh)2(PPh3)2Cl2.57 Hydrogen atoms 
are omitted for clarity. 
 
 
 
Figure 1.14. Molecular drawing from crystallographic data of A) [CpRh(bmtp)]Cl269 and B) 
[CpIr(bmtp)]Cl2.69 Hydrogen atoms and counterions are omitted for clarity. 
 
 
 IR studies of imidazole thione complexes are not common, but thione bonding in 
the [CpM(bmtp)]2+ complexes was also investigated to determine the effects of metal 
binding on the C=S stretch. These IR data show a 15-17 cm-1 shift to higher energy for the 
C=S bonds in Rh- or Ir-bound bmtp and bbtp ligands compared to the unbound ligands, 
but the C=S stretching bands for analogous bptp complexes show no significant shifts 
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compared to that of free ligand (Table 1.1).69 The IR data indicate that these imidazole 
thione ligands are primarily σ and π donors, and that backbonding is minimal.  Similar 
trends were observed for the C=S stretches of the [Cp*MLCl]+ (L = mbit and ebit) 
complexes with shifts in the 10-16 cm-1 range compared to unbound ligands.70 
 The same bmtp, bbtp, and bptp ligands were also used to synthesize the Au(III) 
complexes [AuLCl2]Cl (Figure 1.15).71 Only [Au(bptp)Cl2]Cl was structurally 
characterized, with Au-S bond lengths ranging from 2.340(5) - 2.332(4) Å and C=S bonds 
lengths ranging from 1.68 (2)-1.726(17) Å,71 compared to the C-S bond length for unbound 
bptp (1.6836(10)) Å.69 The differences in C=S bond lengths for [Au(bptp)Cl2]Cl (0.046 Å) 
is greater than for analogous Rh(III) and Ir(III) complexes (0.003 and 0.009 Å, 
respectively). 
Table 1.1. C=S/C=Se infrared stretching bands for thione and selone ligands; ligand structures are shown 
in Figure 1.2. 
Metal complex C=S/C=Se Band (cm-1) 
 
Change from Unbound 
Ligand (cm-1) Ref. 
[CpRh(bmtp)]Cl2 
[CpIr(bmtp)]Cl2 
[CpRh(bptp)]Cl2 
[CpIr(bptp)]Cl2 
[CpRh(bbtp)]Cl2 
[CpIr(bbtp)]Cl2 
1158 
1158 
1157 
1155 
1153 
1154 
15 
15 
4 
2 
16 
17 
69 
69 
69 
69 
69 
69 
[Cp*Ir(mbit)Cl]Cl 
[Cp*Ir(mbis)Cl]Cl 
[Cp*Ir(ebit)Cl]Cl 
[Cp*Ir(ebis)Cl]Cl 
[Cp*Rh(mbit)Cl]Cl 
[Cp*Rh(mbis)Cl][Cp*RhCl3] 
[Cp*Rh(ebit)Cl]Cl 
[Cp*Rh(ebis)Cl]Cl 
1171 
1150 
1150 
1146 
1177 
1152 
1149 
1145 
10 
22 
14 
20 
16 
24 
13 
19 
70 
70 
70 
70 
70 
70 
70 
70 
 
      Trans-[Pt(NH3)2(dmit)2](NO3)2 was synthesized by Jomaa, et al. (Figure 1.16).50 The 
bond length of Pt-S is 2.313(4) Å and the C-S bond length is 1.731(5) Å (Figure 1.16).50 
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The Pt-S bond length in trans-[Pt(NH3)2(Hims)2][NO3]2 (Hims = imidazolidine-2-thione) 
is 2.3260(9) Å, that is in the average of Pt-S bond length values for the similar platinum 
complexes.74 
 
Figure 1.15. Molecular drawing from crystallographic data of [Au(bptp)Cl2]Cl.71 Hydrogen atoms and 
counterions are omitted for clarity. 
 
 
      Platinum complexes have been extremely well-investigated due to the antitumor 
activity of cisplatin and its clinical use in treating cancer. Platinum complexes with 
imidazole thione and selone ligands have been specifically examined for their antitumor 
and antimicrobial activity, as discussed later in the applications sections of this review. 
Similar to cisplatin (cis-Pt(NH3)2Cl2), trans-[Pt(NH3)2(Hims)2][NO3]2 has been 
investigated for its anticancer properties, with two Hims ligands replacing the Cl- leaving 
group ligands on cisplatin.50  
          Silver(I) is the most well-studied 2nd row d-block metal with imidazole thione 
ligands.67,75-76 For example, the structure of dinuclear [Ag2(µ-imdt)2(imdt)2(PPh3)2][NO3]2 
(imdt = 1,3-imidazolidine-2-thione; Figure 1.16) has Ag-S bond lengths for the bridging 
imdt ligands of 2.5674(5) and 2.8120(5) Å, 0.04 and 0.29 Å longer, respectively, than the 
Ag-S bond length for the monodentate imdt ligand (2.5276(5) Å).67 There is no significant 
change in the C=S bond length for bridging and non-bridging imdt ligands (1.711(2) and 
1.712(2) Å, respectively).67  
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 [Cd(MeIms)4][BPh4]2 is an example of a Cd(II) complex with imidazole thione 
ligands that was reported by Dean et al. (Figure 1.16).77 Its structure shows Cd-S bond 
lengths ranging from 2.516(1)-2.563(1) Å, similar to the Ag-S bond lengths of 2.5674(5) 
and 2.5120(5) Å in [Ag2(µ-imdt)2(imdt)2(PPh3)2][NO3]267 and longer than the Pt-S bond 
length in trans-[Pt(NH3)2(dmit)2](NO3)2 2.313(4) Å74. The structure of the Hg(II) complex 
Hg(Me,CH2CH2OH-bimt)Cl2 has a Hg-S bond length of 2.511(4) Å (Figure 1.17).36 The 
 
 
Figure 1.16. Molecular drawing from crystallographic data of A) trans-[Pt(NH3)2(Hims)2][NO3],50 B) 
[Ag2(µ-imdt)2(imdt)2(PPh3)2][NO3]267 and C) [Cd(MeIms)4][BPh4]2.77 Hydrogen atoms and counterions are 
omitted for clarity. 
 
 
Figure 1.17. Molecular drawing from crystallographic data of Hg(Me,CH2CH2OH-bimt)Cl2.36  Hydrogen 
atoms are omitted for clarity. 
 
 
ability of this bimt-derivative ligand (Figure 1.2) to detoxify organomercurial compounds 
through ligand exchange reactions is discussed in the heavy metal detoxification section of 
this review. 
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 Imidazole selone complexes. Imidazole selone complexes with 2nd and 3rd row d-
block metal ions are much less studied than their thione counterparts, and only a few 
publications describe these types of complexes.38,53,68,70,72,78,81-83 For example,  
[Cp*Rh(mbis)Cl]Cl,69 [Cp*Ir(mbis)Cl]Cl,69 Au2(C6F5)2(mbis),71 and Au2(C6F5)6(ebis)72 
have been synthesized and structurally characterized (Figure 1.18). The Rh-Se bond in 
[Cp*Rh(mbis)Cl]Cl70 (2.528(1) Å) is slightly longer than the Ir-Se bond in  
[Cp*Ir(mbis)Cl]Cl70 (2.505(1) Å), and the Au(I)-Se bond in Au2(C6F5)2(mbis)72 length is 
shorter than 2.4263(5) Å and Au(III)-Se are and 2.4607(6) Å, respectively. In addition, the 
range of the C=Se bonds lengths in these four complexes above are 1.867(6)-1.894(4) 
Å.70,72   
 
Figure 1.18. Molecular drawing from crystallographic data of A) [Cp*Rh(mbis)Cl]Cl,70                                           
B) [Cp*Ir(mbis)Cl]Cl,70 C) Au2(mbis)(C6F5)6,72  and D) Au2(ebis)(C6F5)2.72 Hydrogen atoms and 
counterions are omitted for clarity. 
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 Dinuclear Pd(II) and Pt(II) complexes (bbmimise)2Pd2Cl4 and (bbmimise)2Pt2Cl4 
complexes (Figure 1.19) are analogous dinuclear complexes where the metal ions are 
bridged by two bidentate bbmimise ligands.  In (bbmimise)2Pd2Cl4, Pd-Se bond lengths 
range from 2.4329(8)-2.4414(8)Å and C-Se bond lengths range from 1.870(7)-1.882(6) 
Å).53 In the analogous (bbmimise)2Pt2Cl4, the Pt-Se bond lengths range from 2.415(3)-
2.431(3)Å and C-Se bond lengths range from 1.870(2)-1.890(2) Å.53 The Pt-Se bonds are 
slightly shorter than the Pd-Se bonds, whereas the C-Se bond length similar for both 
complexes.53  
 
Figure 1.19. Molecular drawing from crystallographic data of A) (bmimise)2Pd2Cl4 and                              
B) (bbmimise)2Pt2Cl4.53 Hydrogen atoms are omitted for clarity. 
 
 
 In addition, the dmise ligand has been used to synthesize Cd(II) complex.68 The 
structure of [Cd(dmise)4][PF6]2 (Figure 1.20) shows a Cd-Se bond length of 2.609(2) Å and 
a C-Se bond length of 1.852(10) Å.68 Due to the high affinity of selenium ligands for Cd(II), 
understanding the bonding in this complex allows researchers to explore the possibility of 
using imidazole selone ligands to reduce cadmium toxicity.68 
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Figure 1.20. Molecular drawing from crystallographic data of [Cd(dmise)4][PF6]2.68 Hydrogen atoms and 
counterions are omitted for clarity. 
 
 
 All the thione and selone complexes with 2nd and 3rd row d-block metals that have 
been discussed in this Chapter gave fairly consistent M-S or M-Se bond lengths based on 
the identity of the metal ion. In addition, the C=S and C=Se bond length values of the 
bound imidazole thione or selone ligands are generally the same as for the unbound ligands.  
Notable exceptions to this trend are the very low-valent M(tmeimt)(CO)5 (Mo and W) 
complexes with C=S bond lengths slightly longer than that of the  tmeimt ligand.65 The 
infrared spectroscopy of these metal complexes with imidazole thione and selone ligands 
has not been investigated deeply, except for the complexes shown in Table 1.1. Given the 
differences in C=S or C=Se stretches between complexes, this remains an interesting area 
for investigation.  In addition, studies reporting the coordination chemistry of imidazole 
selone ligands are sparse, with much room for additional work in this area. 
 
1.3. Applications of imidazole thione and selone complexes 
 Imidazole thione complexes with 2nd and 3rd row d-block metal ions have a wide 
range of applications in both biological and materials directions. Although imidazole 
selone complexes of these metals have received less attention than their thione 
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counterparts, their biological activity and ability to prevent metal toxicity also have been 
explored.34-36,42,86 This review focuses on the four major applications for these complexes: 
as antitumor agents, as antimicrobial agents, as complexes that ameliorate heavy-metal 
toxicity, and as catalysts. 
 Antitumor activity. Since the discovery of cisplatin, cis-Pt(NH3)2Cl2, in the 1960s85 
and its current clinical use in chemotherapy,86 developing cisplatin analogs with 2nd and 3rd 
row d-block metal complexes has been a major focus of bioinorganic chemical     
research.87-88 Cisplatin’s toxicity and narrow effective concentration range for antitumor 
activity significantly limit use of this chemotherapeutic drug.87-88 Thus, researchers are 
developing cisplatin analogs with lower toxicity and higher efficacy for killing various 
cancer cell lines.87-88 Several cisplatin analogs with M-S63,69,71,75 and M-Se49-50,89 bonds 
have been synthesized and investigated for their antitumor activities, including complexes 
that contain imidazole thione47,50,74,90 and selone48-49 ligands.  
 The antitumor activity of cisplatin and analogous complexes depends on 
dissociation of the chloride or other, non-amine ligands and their replacement by water 
molecules that facilitates metal binding to the aromatic N7 position of guanine and adenine 
bases in DNA.91 Because of this tendency for ligand exchange, one disadvantage of 
cisplatin and analog complexes is binding to proteins in the blood through the sulfur atoms 
of cysteine residues.87-88,91 Including imidazole thione and selone ligands in the 
coordination sphere of the Pt complexes may reduce undesirable binding due to thione and 
selone similarity to and competition with biological sulfur and selenium ligands such as 
cysteine, ergothioneine, and selenoneine.92  
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 Most cisplatin analogs with imidazole thione47,50,74,90 and selone48-49 ligands 
effectively kill cancer cells based as measured by the concentration of complex required to 
kill 50% of cells (EC50 value).  For example, cis-[Pt(PEt3)2L2]Cl2 (L = imt, imtMe, imtMe2, 
imtEt2) complexes have been tested for their in vitro cytotoxic effects against human 
cervical (HeLa), breast (MCF-7), lung (A549), and colon (HTC15) cancer cell lines.  All 
of these Pt(II)-thione complexes show enhanced cytotoxicity (EC50 values of 1.4-16 µM) 
compared to the currently used drugs cisplatin (EC50 values of 19-42 µM) and carboplatin 
(EC50 values of 56-71 µM), Table 1.2.74 
Table 1.2. EC50 values for cisplatin, carboplatin, and Pt-thione74 and -selone48 complexes in human cancer 
cell lines. 
Compound 
EC50 values (µM) 
HeLa A549 MCF7 HCT15 MDA-231 
Cisplatin, Pt(NH3)2Cl2 19 ± 2 42 ± 1 22 ± 1 30 ± 2 − 
Carboplatin 56 ± 2 71 ± 3 56 ± 3 64 ± 2 − 
cis-[Pt(PEt3)2(imt)2]Cl2 1.4 ± 0.3 3.5 ± 0.7 5 ± 1 7 ± 1 − 
cis-[Pt(PEt3)2(imtMe)2]Cl2 1.8 ± 0.3 3.9 ± 0.5 2.6 ± 0.9 8.6 ± 0.9 − 
cis-[Pt(PEt3)2(imtMe2)2]Cl2 1.5 ± 0.2 2.4 ± 0.3 3.8 ± 0.6 4.2 ± 0.7 − 
cis-[Pt(PEt3)2(imtEt2)2]Cl2 10 ± 2 13 ± 1 14 ± 1 16 ± 1 − 
Cisplatin 3.6 ± 0.3 − − − 6.3 ± 0.1 
trans-[Pt(NH3)2(imsEt)2][NO3]2 2.1 ± 0.2 − − − 4.4 ± 0.2 
trans-[Pt(NH3)2(imsiPr)2][NO3]2 3.1 ± 0.3 − − − 5.7 ± 0.2 
 
  
      Pt(II) complexes with imidazole selone ligands also have been studied as antitumor 
agents by Alhoshani et al.48 Cytotoxicity of trans-[Pt(NH3)2L2][NO3]2 (L = EtImse  and 
iPrImse) complexes were studied in cervical (HeLa) and breast cancer (MDA-231) cell 
lines, and both Pt-selone complexes are more effective than cisplatin (Table 1.2).48 Thus, 
in these two studies, the Pt(II) complexes with imidazole thione and selone ligands show 
between 5-18 times greater activity for killing cancer cells than cisplatin.  The high activity 
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of these Pt(II)-imidazole thione complexes is promising, and the next step will be testing 
these complexes in vivo to assess toxicity and to compare these results to cisplatin.  
 Antimicrobial activity. Emerging new infectious diseases and the increasing 
number of multi-drug resistant microbial pathogens are challenging problems,93 and 
developing new antimicrobial agents is of critical importance. Although only a few 
complexes have been investigated for their antimicrobial properties, imidazole thione and 
selone complexes of Pd(II), Ag(I) and Cd(II) show promising antimicrobial      
activities.37,43-44,67,84,93  For example, the activity of [Pd(imt)4]I2 was tested against two gram 
positive (S. aureus, and B. subtilis) and two gram negative (E. coli, and P. aeruginosa) 
strains and compared to the activity of Imipenem.93 The synthesized complex 
[Pd(HIms)4]I2 exhibit fair activity compared to antibiotic control, the authors used 
Petra/Osiris/Molinspiration (POM) analysis to predict the biological activities of these 
complexes by determining the relationships between their steric/electrostatic properties 
and observed biological activity with pharmacophore groups.93 These relationships help 
model potential ligand-receptor interactions and indicate that ligands with C=S groups 
have potential antimicrobial behavior.93   
 Heavy metal detoxification. Organomercury compounds, including methylmercury 
(MeHg+), are very highly toxic34-36,84 and have negative environmental effects.34-36 Toxicity 
of organomercurials is an ongoing problem, since anthropological activities such as 
industrial processes have increased environmental mercury levels.35 Methylmercury 
(MeHg+) toxicity is due to its lipophilic properties and its high affinity for coordinating 
biological sulfur- and selenium-containing ligands, such as cystine, selenocysteine, and 
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methionine in proteins.36 Synthesis and characterization of mercury imidazole thione and 
selone complexes and examination of their reactivity is vital to understanding the 
biological effects of mercury and to developing new methods to detoxify methylmercury 
and other organomercury species.34  
 A few heterocyclic thione and selone mercury complexes have been synthesized 
and their reactivities examined to provide insight into mercury detoxification in biological 
systems.34-36,84 Ligand exchange reactions with mercury or its complexes can be a 
promising solution to remove mercury from biomolecules. Since imidazole thione and 
selone compounds have high affinity for mercury coordination, they have been used to 
explore these ligand exchange reactions with organomercurials.36 In one example reported 
by Roy, et al.,36 benzimidazole thione and selone ligands (R,R’-bimt and R,R’-bimse, 
respectively, with R = Me, R’ = CH2CH2OH) preferentially coordinate glutathione-bound 
MeHg+ in a 1:1 ratio.  Bimt/bimse-Hg binding generates a partial positive charge on the 
carbon atom of the C=S/C=Se group, leading to loss of S/Se from the imidazole ring and 
conversion of MeHg+ to less toxic and water-soluble HgS nanoparticles (Scheme 1.1).36 
NN
EHgR
HONH
O
SHgR
 + HgE NPs + R2Hg+ GSHMe,CH2CH2OH-bimt/bimse
GSH-HgR
NN
O
HO
E = S; Me,CH2CH2OH-bimt
       Se; Me,CH2CH2OH-bimse  
Scheme 1.1. Organomercury removal from glutathione (GSH) and conversion to HgS nanoparticles (NPs) 
upon treatment with imidazole thione or selone ligands (bimt or bimse). 
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 Separately, the products of this type of ligand exchange reaction were studied by 
treating ArHgCys-GSH (Ar = 2-vinyl, 2-phenylpyridine) with Me, CH2CH2OH-bimt or 
Me,CH2CH2OH-bimse (Figure 1.2) in a 1:2 molar ratio at pH 9. An ArHg(Me,CH2CH2OH 
bmit/bmise) complex forms that is in equilibrium with the ArHgCys-GSH complex, as 
identified by high-pressure liquid chromatography (Scheme 1.1).36 This Me,CH2CH2OH-
bimt/bmise-HgAr complex gradually decomposes to form HgE nanoparticles, Ar2Hg, and 
GSH (Scheme 1.1).36 The ArHg-selone complex is highly unstable in solution, resulting in 
much faster degradation to HgSe nanoparticles than the analogous thione.36 Understanding 
the ligand exchange reactions that can remove mercury from biomolecules may contribute 
to development of effective drugs to reduce heavy metal toxicity.  
 Catalytic applications. The electronic properties, ease and versatility of nitrogen 
substitution, and stability of the C=S and C=Se bonds make imidazole thiones and selones 
excellent ligands for heavy metal catalysts.94 Imidazole thione and selone complexes have 
been designed as promising catalysts for activation for transfer hydrogenation,38 
Suzuki−Miyaura and Sonogashira coupling reactions,94 and norbornene polymerization.69 
For example, the ability of (η6‑C6H6)RuLCl[PF6] (L = benzoimithione (1) or 
benzoimiselone (2); Figure 1.2) complexes to catalyze hydrogen transfer reactions 
(Scheme 1.2).38 In this work, catalyst complexes 1 and 2 (0.1-0.5 mol %) were used to 
transform eight substrates including benzaldehyde, 4-methylacetophenone, or 
cyclopentanone to the corresponding alcohols at 80 ºC using 2-propanol, glycerol, citric 
acid, ascorbic acid, and formic acid as hydrogen sources. Using 4-methylacetophenone, 
acetophenone, or cyclopentanone as the ketone and 2-propanol as the hydrogen source 
24 
 
R1 R2
O
    
R1 R2
OH
 Complex 1 or 2
H-source
 
Scheme 1.2. Hydrogen transfer by [(η6‑C6H6)RuLCl][PF6] (L= benzoimithione (1) or benzoimiselone (2) in 
the presence of a hydrogen source (R1, R2 = alkyl or aryl). 
 
 
results in 90-95% conversion, while using glycerol as the hydrogen source gives 83-90% 
product conversion. The benzoimiselone-Ru complex 2 is more efficient at hydrogen 
transfer compared to the thione analog 1.38 Development of novel hydrogen transfer 
catalysts such as these Ru-imidazole thione and selone complexes has the potential for 
great impact, since hydrogen transfer is a very important reaction in the production of 
pharmaceuticals.38  
 
1.4 Conclusions and Outlook 
 Due to the variety of applications of imidazole thione and selone of 2nd and 3rd row 
d-block metal ions complexes, synthesis of new thione and selone complexes will continue 
to improve their biological, catalytic, and heavy metal detoxifying activities. In addition, 
fully understanding their versatile coordination chemistry will require the synthesis of 
unexplored types of thione and selone ligands and coordination to unexamined metal 
oxidation states. Overall, such imidazole thione and selone complexes are promising for 
new applications in medicine and industry. Synthesis of Pt-thione and -selone antitumor 
agents with higher activity and less toxicity compared to cisplatin opens the door for 
clinical applications of these complexes in the future. In addition, in the development of 
new antimicrobials, imidazole thione complexes may contribute strongly in this field due 
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to identification of the bioactivity of the C=S moiety. There are still major gaps in 
understanding heavy metal toxicity, and exploring the coordination chemistry of mercury-
imidazole thione and selone complexes is helping to elucidate mechanisms for treating this 
toxicity.  In the future, such compounds may be developed as heavy metal detoxifying 
drugs.  
 
1.5 Using Ruthenium Solvato Complexes as an Entry into Ruthenium Thione and 
Selone Complexes 
  The variety of imidazole thione and selone complexes with 2nd and 3rd row d-block 
metals, as well as their applications in catalysis and medicine was the focus of the review 
in Chapter 1.   This overview of 2nd and 3rd row d-block metal ion complexes with imidazole 
thione and selone ligands provides a foundation for understanding the novelty of 
synthesizing homoleptic and hetroleptic ruthenium-thione and -selone complexes. 
 To synthesize homoleptic thione and selone ruthenium complexes requires suitable 
ruthenium starting materials. The lability of acetonitrile and DMSO ligands makes these 
ruthenium complexes valuable synthons for a variety of ruthenium complexes. The 
homoleptic [Ru(NCCH3)][BF4]2 and heteroleptic [Ru(NCCH3)5(DMSO)][BF4]2, 
[Ru(NCCH3)4(DMSO)2][BF4]2, and [Ru(NCCH3)2(DMSO)3Cl][BF4]1.5[Cl]0.5[Na] solvato 
Ru(II) complexes were synthesized and fully characterized for use as novel ruthenium 
starting materials (Chapter 2).  The ease of synthesis for these complexes will allow greater 
entry into the synthesis of a variety of Ru(II) complexes, including potential anticancer 
ruthenium species. 
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 Novel Ru(III) complexes with imidazole thione and selone ligands of the formula 
[RuL6]Cl3 and Ru(II) complexes with formulae [RuL6][BF4]2 and RuCl2L4  (L = MMI, 
dmit, dmise) were synthesized and characterized (Chapter 3). In addition, the kinetics of 
the reactivity of the air-stable [RuL6]3+ with H2O2 are also reported. The ability of 
[RuMMI6]Cl3 to prevent oxidative DNA damage was significantly higher than for MMI 
alone, indicating that these complexes have substantial antioxidant activity. 
  Chapter 4 describes the synthesis and characterization of novel Ru(II) nitrosyl 
complexes with imidazole thione or selone ligands of the formula [Ru(NO)L4Cl][BF4]2 (L 
= dmit or dmise). These complexes were synthesized with AgNO3 as the NO source, a 
much simpler reagent to work with compared typical NO addition reagents. This important 
contribution will open the door widely to synthesize nitrosyl ruthenium complexes with 
possible biological activities.   
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CHAPTER TWO 
 
SYNTHESIS, CHARACTERIZATION, AND STRUCTURES OF RUTHENIUM(II) 
COMPLEXES WITH MULTIPLE SOLVATO LIGANDS 
 
2.1 Introduction 
 Ruthenium complexes with monodentate, photolabile ligands such as cis-
[Ru(phpy)(phen)(NCCH3)2][PF6] (phpy = 2-phenylpyridine; phen = 1,10-phenanthroline) 
and cis-[Ru(phpy)(bpy)(NCCH3)2][PF6] (bpy = 2,2-bipyridine)1 as well as cis- and trans-
RuCl2(DMSO)4 (DMSO = dimethyl sulfoxide) have been investigated as potential 
photodynamic therapy (PDT) agents to treat cancer.1-2 Dimethyl sulfoxide and 
acetonitrile are monodentate, labile ligands, so homoleptic and heteroleptic ruthenium 
complexes of these ligands also provide excellent starting materials for entry into 
synthetic ruthenium chemistry.3-9 As befits their synthetic utility, many Ru(II) complexes 
with multiple acetonitrile ligands are reported, including [CpRu(NCCH3)3][PF6] (Cp = 
cyclopentadienyl),6,10 cis-[Ru(nbd)(η2-C3H5)(NCCH3)2][BF4] (nbd = norbornadiene),7 
and [Ru(phpy)(phen)(NCCH3)2][PF6].2  
 Although the lability of the Ru-coordinated acetonitrile ligands gives rise to 
several advantages,1,3,5-9 including synthesis of complexes with less labile ligands using 
acetonitrile complexes as starting materials,3-4,9,11-12 synthesis of Ru(II) complexes with 
exclusively acetonitrile ligands is challenging when RuCl3·3H2O, RuCl2(DMSO)4, and 
RuCl2(PPh3)3 are used as starting materials because most of the resulting ruthenium 
complexes retain chloride, DMSO, or PPh3 ligands, respectively.3,13-15 Alternatively, the 
[Ru(H2O)6]2+ complex can be used  as a synthon, but this complex has solubility issues in 
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organic solvents, and the presence of the aqua ligands can hinder further water-sensitive 
synthetic steps.4,9,11  Aqua ligand basicity can also exclude further synthesis with ligand 
classes such as amines,9 and aqua ligands can promote complex decomposition through 
deprotonation reactions, limiting their use in starting materials.9,14 Instead, [Ru(H2O)6]2+ 
has itself been used to synthesize [Ru(NCCH3)6][OTs]2 and [Ru(NCCH3)6][OTf]2 
complexes (OTs = p-toluene sulfonate; OTf = trifluoromethane sulfonate),16 but 
purification of [Ru(H2O)6]2+ requires many steps.17-18     
 [Ru(NCCH3)6][ZnCl4] and [Ru(NCCH3)6][BF4]2 (1) have been synthesized using 
various methods,3,9 but several difficulties accompany the reported synthesis and uses of 
these complexes as starting materials. The [ZnCl4]2- counterion in the former complex 
can interact with metal-binding species instead of, or in addition to, the ruthenium-
containing cation. The reported preparation and purification of complex 1 takes several 
days and requires several synthetic steps.9 In this work, we have synthesized complex 1 
in higher yield and in shorter times compared to previously reported methods.3,9 In 
addition, the previously reported RuCl2(DMSO)4 complex19-21 was used to synthesize 
mixed Ru(II) acetonitrile/DMSO complexes with varying numbers of acetonitrile and 
DMSO ligands (2-5). The work presented in this Chapter is published in Inorganica 
Chimica Acta (Abbas, M. A.; McMillen, C. D.; Brumaghim, J. L Inorg. Chim. Acta 2017, 
468, 308-315), and reproduction in this dissertation is allowed by the publisher. 
 
2.2 Results and Discussion 
 The reported method for synthesis of  [Ru(NCCH3)6][BF4]2 (1)9 does not always 
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reduce Ru(III) in RuCl3·3H2O, depending on the source of the ruthenium chloride 
hydrate starting material. Therefore, a more robust synthesis was developed by modifying 
methods reported for synthesis of 1 and [Ru(NCCH3)6][ZnCl4].3 Instead of directly 
isolating [Ru(NCCH3)6][ZnCl4] in low yield as reported by Anzellotti and Briceño,3 
excess AgNO3 was added to the reaction mixture to remove the [ZnCl4]2- counterion and 
Cl- ligands as ZnCl2 and AgCl precipitates, respectively (Scheme 2.1). Addition of NaBF4 
to exchange the resulting nitrate counterion for tetrafluoroborate yields complex 1. This 
modified synthetic procedure reduces the reaction time to form complex 1 from 13 h9 to 8 
h and improves the yield from 60% for [Ru(NCCH3)6][BF4]2 (1) and 36% for 
[Ru(NCCH3)6][ZnCl4] in the reported syntheses3,9 to 75%.  
 
Scheme 2.1. Syntheses of ruthenium complexes with multiple solvato ligands. 
 
  Synthesis and characterization of Ru(II)-acetonitrile/DMSO complexes. The 
reported RuCl2(DMSO)4 complex19-21 was used as a starting material to synthesize novel 
mixed-solvato Ru(II) complexes 2, 3, 4, and 5. In RuCl2(DMSO)4, three of the four 
DMSO ligands coordinate Ru(II) through the sulfur atom, whereas the remaining DMSO 
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ligand binds through the oxygen atom, indicated as [RuCl2(DMSO-S)3(DMSO-O)].20-24 
The weaker O-bound DMSO is replaced first;21 therefore, only this bound DMSO and 
one chloride are replaced by acetonitrile to form the bis-acetonitrile complex 2 (Scheme 
2.1) when the reaction is stirred for 4 h without heating. Upon stirring for 8 h, both 
chloride ligands and two DMSO ligands are replaced by acetonitrile ligands to afford 
complex 3.  
 Upon heating RuCl2(DMSO)4 to reflux in acetonitrile with excess AgNO3, the 
two chlorides and three of the four DMSO ligands are replaced with acetonitrile to form 
complex 4 (Scheme 2.1).  [Ru(NCCH3)5(DMSO)][BF4]2 (5) was synthesized by treating 
complex 4 with NaBF4 in acetonitrile to replace the nitrate counterion (Scheme 2.1).  
Complexes 1-5 are stable as solids, but readily lose solvato ligands under vacuum. The 
facile synthetic methods and high yields of these mixed solvato complexes make them 
valuable as potential synthons for a variety of heteroleptic ruthenium complexes.    
 Spectroscopic characterization of Ru-solvato complexes. In infrared (IR) 
spectroscopic measurements, the two bands for the C≡N stretches of the acetonitrile 
ligands in Ru(II) complexes 1-5 were observed between 2296 and 2332 cm-1 (Table 2.1), 
higher in energy than for unbound acetonitrile (2283 cm-1 25) and typical of Ru(II) 
binding.9,25-26  For complex 1, these bands are observed at 2296 and 2332 cm-1, matching 
literature reports.3,9  
  The IR spectrum of the cis-RuCl2(DMSO)4 complex used as a starting material 
shows two bands for the S-O stretches at 1120 and 1090 cm-1, arising from the non-
equivalent DMSO-S ligands, shifted higher in energy than the S-O stretch of unbound 
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Table 2.1. IR stretching bands for C≡N and S-O in complexes 1-5. 
Complex C≡N (cm-1) S-O (cm-1) Reference 
[Ru(NCCH3)6][BF4]2 (1) 2296, 2332 -       9 
[RuCl(NCCH3)2(DMSO)3][BF4]1.5[Cl]0.5[Na] (2) 2300, 2332 1121, 1067 This work 
[Ru(NCCH3)4(DMSO)2][BF4]2 (3) 2296, 2325 1122, 1070 This work 
[Ru(NCCH3)5(DMSO)][NO3]2 (4) 2300, 2324 1127, 1035 This work 
[Ru(NCCH3)5(DMSO)][BF4]2 (5) 2303, 2324 1123, 1029 This work 
 
DMSO (1055 cm-1) due to Ru(II) coordination. In contrast, the S-O stretch of the DMSO-
O ligand in cis-RuCl2(DMSO)4 shifts to significantly lower energy (928 cm-1) due to a 
decrease in the S-O bond order upon Ru(II)-O binding.20  In the IR spectrum of complex 
2, with three bound DMSO ligands, S-O stretches are observed at 1121 and 1067 cm-1, 
consistent with only sulfur-bound DMSO ligands, and indicating that acetonitrile has 
replaced the DMSO-O ligand.20 Similarly for complex 3 with two bound DMSO ligands, 
these S-O stretches occur at similar energies and indicate DMSO-S binding.  In the IR 
spectrum of complexes 4 and 5, the second S-O stretch shifts ~30 cm-1 lower in energy 
when only one DMSO ligand is coordinated. 
 The single resonance from the bound acetonitrile at δ 2.53 in D2O in the 1H NMR 
spectra for Ru(II) complex 1 matches previous reports9 and is shifted downfield 
compared to that of unbound acetonitrile (δ 2.06 in D2O27).  Complexes 2-5 also have 
similar acetonitrile ligand resonances in their 1H NMR spectra, consistent with Ru(II)-
acetonitrile complex 1 (Table 2.2). The three DMSO ligands in 2 give rise to two 
resonances with a 2:1 integration ratio, corresponding to DMSO ligands trans to DMSO 
and chloride, respectively, similar to 1H NMR shifts observed previously for Ru 
complexes with multiple DMSO ligands.20,26 Similarly, the acetonitrile ligands in 3 give 
rise to two singlet resonances with a 1:1 integration ratio, corresponding to acetonitrile  
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Table 2.2. 1H NMR chemical shifts (δ) in D2O of the solvato ligands in complexes 1-5.  
 
 
ligands trans to acetonitrile or DMSO. In 3, the DMSO ligand resonance is a singlet, 
indicating that the [Ru(NCCH3)4(DMSO)2]2+ adopts a cis geometry in solution with both 
DMSO ligands trans to acetonitrile. In all cases, the Ru-bound DMSO ligands are shifted 
downfield from unbound acetonitrile (δ 2.71 in D2O27), similar to resonance shifting 
observed for bound acetonitrile.  
 Complexes 4 and 5 show two sets of singlet resonances for the DMSO and 
acetonitrile ligands in approximately 2:3 ratios for 4 and 1:3 ratios for 5 that together 
have the expected integrations of 6H for the DMSO resonances and 15H for the 
acetonitrile resonances.  This doubling of each resonance may result from outer-sphere 
interactions or ligand dissociation in solution.  Removing all unbound solvent before 
acquiring NMR spectra was not possible, since the solvato ligands are labile and readily 
lost under vacuum and complexes 2, 3, and 4 crystalized with unbound acetonitrile in the 
lattice. In addition, 1H NMR spectra in D2O for these mixed-solvato complexes change 
over hours to days, particularly for complex 3, indicating isomerization and/or 
decomposition in solution. 
  X-ray structural analysis. For the hexakis(acetonitrile) complex 1, two 
polymorphs were observed in this study, denoted 1a and 1b.  The polymorphs were 
Complex NCCH3 DMSO-S Reference 
[Ru(NCCH3)6][BF4]2 (1) 2.53 - 3,9 
[RuCl(NCCH3)2(DMSO)3][BF4]1.5[Cl]0.5[Na] (2) 2.59 3.49, 3.46 This work 
[Ru(NCCH3)4(DMSO)2][BF4]2 (3) 2.61, 2.59 3.46 This work 
[Ru(NCCH3)5(DMSO)][NO3]2 (4) 2.55, 2.53 3.44, 3.43 This work 
[Ru(NCCH3)5(DMSO)][BF4]2 (5) 2.56, 2.53 3.43, 3.42 This work 
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distinguishable based on the physical morphology of the crystals, and often were found to 
crystallize concurrently with one another.  Complex 1a crystallizes as block-like crystals, 
and its structure is consistent with that previously reported for [Ru(NCCH3)6][BF4]2 in 
space group P21/c, though an improved refinement is presented in the present study from 
data collected at 100 K. Complex 1b crystallizes as columnar crystals, with the same 
chemical formula [Ru(NCCH3)6][BF4]2, but crystallizing in space group C2/m.  In both 
polymorphs, the Ru(II) ions are bound to six acetonitrile ligands in a distorted octahedral 
geometry (Figure 2.1), and the Ru atom sits on a center of symmetry, rigorously 
enforcing 180° trans-N-Ru-N angles.  A small amount of distortion is observed about the 
cis-N-Ru-N angles, ranging from 88.06(4) to 91.94(4)° in 1a and 87.63(8) to 92.37(8)° in 
1b (Table 2.3).  The observed average Ru-N bond distances in 1a (Ru-N = 2.022(1) Å) 
and 1b (Ru-N = 2.023(3) Å) are consistent with those previously reported for ruthenium 
centers having six acetonitrile ligands coordinated to Ru(II) (2.030(6) Å),3 as well as with 
other acetonitrile-rich Ru(II) complexes such as [Ru(NCCH3)5I],28 
[Ru(NCCH3)5(PPh3)],29 and [Ru(NCCH3)Cl],30 all having Ru-N interatomic distances  
 
Figure 2.1. Coordination geometries about the Ru(II) centers for hexakis(acetonitrile) polymorphs 1a and 
1b, respectively.  Atoms are shown with 50% probability ellipsoids, with hydrogen atoms, counterions, and 
solvent molecules omitted for clarity.  
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around 2.00-2.04 Å for ligands not experiencing elongation from trans effects. 
   Polymorphs 1a and 1b do exhibit certain subtle local structural differences.  For 
example, there is a slight elongation of the axial Ru-N1 bonds relative to the equatorial 
Ru-N2 bonds in 1b that is not observed in 1a.  Primarily, the polymorphs differ in their 
packing arrangements of the [Ru(NCCH3)6]2+ and [BF4]- ions (Figure 2.3).  The packing 
of 1b is likely affected by disorder of two of the fluorine sites (half-occupied general 
positions) of the tetrafluoroborate anion, whereas in 1a the tetrafluoroborate anion is 
fully-ordered at all the fluorine sites. 
 
Table 2.3. Selected interatomic distances (Å) and angles (°) for hexakis(acetonitrile) complexes 1a and 1b. 
1a 
[Ru(NCCH3)6](BF4)2 
1b 
[Ru(NCCH3)6](BF4)2 
Ru1−N1 (×2) 2.0218(11) Ru1−N1 (×2) 2.032(3) 
Ru1−N2 (×2) 2.0218(10) Ru1−N2 (×4) 2.019(2) 
Ru1−N3 (×2) 2.0217(10)   
N1−Ru1−N1 180 N1−Ru1−N1 180 
N1−Ru1−N2 89.07(4) 
90.93(4) 
N1−Ru1−N2 87.63(8) 
92.37(8) 
N1−Ru1−N3 89.78(4) 
90.22(4)) 
N2−Ru1−N2 (trans) 180 
N2−Ru1−N2 180 N2−Ru1−N2 (cis) 88.41(13) 
91.59(13) 
N2−Ru1−N3 88.06(4) 
91.94(4) 
  
N3−Ru1−N3 180   
 
 The coordination geometries of Ru(II) complexes 2, 3, 4, and 5 with mixed 
acetonitrile and DMSO coordination are shown in Figure 2.2, with selected interatomic 
distances and angles in Table 2.4. These complexes display a range of ratios of the 
coordinated ligands.  Complex 2 exhibits acetonitrile:DMSO of 2:3 with an additional 
non-solvato Cl ligand, complex 3 is comprised of 4:2 acetonitrile:DMSO, and complexes 
4 and 5 have acetonitrile:DMSO in a 5:1 ratio.  Complex 5 was crystallized from 
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acetonitrile in two different forms: without crystallized solvent molecules as 
[Ru(NCCH3)5(DMSO)][BF4]2 (Figure 2.2 and Table 2.4) in space group P21/c, and as an 
acetonitrile solvate [Ru(NCCH3)5(DMSO)][BF4]2·2CH3CN (Figure 2.4 and Tables 2.8-
2.9) in space group P-1.  Data for six-coordinate Ru(II) complexes involving mixed 
acetonitrile and DMSO ligands are somewhat lacking in the structural literature.  
Previously reported crystal structures with mixed acetonitrile and DMSO coordination to 
Ru(II) also have non-solvato ligands bound to the Ru center, including [Ru(phen-NH-
phen)(NCCH3)(DMSO)] (N,N-bis(1,10-phenanthroline-2-yl)amine),31 
[RuCl2(NCCH3)(DMSO)3],32 and [Ru(cyclen)(NCCH3)(DMSO)] (cyclen = 1,4,7,10- 
tetraazacyclododecane).32-34 Complex 2, resulting from acetonitrile treatment of  
 
Figure 2.2. X-ray diffraction structures for complexes 2, 3, 4, and 5, with mixed acetonitrile and DMSO 
coordination.  Atoms are shown as 50% probability ellipsoids, with hydrogen atoms, counterions, and 
solvent molecules omitted for clarity. 
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Table 2.4. Selected interatomic distances (Å) and angles (°) for complexes 2, 3, 4, and 5.  The structure of 
complex 3 contains four unique Ru centers, and the Ru1 center is tabulated here as a representative 
example. 
2 
[RuCl(NCCH3)2(DMSO)3] 
[BF4]1.5[Cl]0.5[Na]·xCH3CN 
3 
[Ru(NCCH3)4(DMSO)2] 
[BF4]2·0.5CH3CN 
4 
[Ru(NCCH3)5(DMSO)] 
[NO3]2·2CH3CN 
5 
[Ru(NCCH3)5(DMSO)] 
[BF4]2 
Ru1−N1 2.073(3) Ru1−N1 2.020(9) Ru1−N1 2.031(2) Ru1−N1 2.042(5) 
Ru1−N2 2.085(3) Ru1−N2 2.015(10) Ru1−N2 2.0240(19) Ru1−N2 2.023(5) 
Ru1−S1 2.2902(8) Ru1−N3 2.101(9) Ru1−N3 2.0233(19) Ru1−N3 2.012(5) 
Ru1−S2 2.2832(8) Ru1−N4 2.073(9) Ru1−N4 2.0765(19) Ru1−N4 2.101(5) 
Ru1−S3 2.2896(8) Ru1−S1 2.268(3) Ru1−N5 2.0299(19) Ru1−N5 2.029(5) 
Ru1−Cl1 2.4253(8) Ru1−S2 2.275(3) Ru1−S1 2.2621(6) Ru1−S1 2.2580(14) 
N1−Ru1−N2 89.32(11) N1−Ru1−N2 175.6(4) N1−Ru1−N2 174.94(7) N1−Ru1−N2 175.06(18) 
N1−Ru1−S1 92.20(8) N1−Ru1−N3 90.6(3) N1−Ru1−N3 91.21(7) N1−Ru1−N3 87.77(18) 
N1−Ru1−S2 88.64(8) N1−Ru1−N4 88.3(3) N1−Ru1−N4 85.37(7) N1−Ru1−N4 89.14(18) 
N1−Ru1−S3 178.16(8) N1−Ru1−S1 93.9(2) N1−Ru1−N5 89.50(7) N1−Ru1−N5 93.39(18) 
N1−Ru1−Cl1 85.56(8) N1−Ru1−S2 89.0(2) N1−Ru1−S1 92.33(5) N1−Ru1−S1 91.23(13) 
N2−Ru1−S1 177.79(9) N2−Ru1−N3 86.8(4) N2−Ru1−N3 90.36(7) N2−Ru1−N3 88.55(18) 
N2−Ru1−S2 91.18(8) N2−Ru1−N4 88.0(4) N2−Ru1−N4 89.88(7) N2−Ru1−N4 87.59(18) 
N2−Ru1−S3 88.92(8) N2−Ru1−S1 89.7(3) N2−Ru1−N5 88.63(7) N2−Ru1−N5 90.19(19) 
N2−Ru1−Cl1 88.58(8) N2−Ru1−S2 93.6(3) N2−Ru1−S1 92.54(5) N2−Ru1−S1 92.05(13) 
S1−Ru1−S2 90.46(3) N3−Ru1−N4 86.6(4) N3−Ru1−N4 88.05(7) N3−Ru1−N4 90.23(18) 
S1−Ru1−S3 89.55(3) N3−Ru1−S1 92.4(3) N3−Ru1−N5 176.18(7) N3−Ru1−N5 177.81(17) 
S1−Ru1−Cl1 89.94(3) N3−Ru1−S2 179.6(3) N3−Ru1−S1 87.39(5) N3−Ru1−S1 89.83(13) 
S2−Ru1−S3 91.93(3) N4−Ru1−S1 177.6(2) N4−Ru1−N5 88.26(7) N4−Ru1−N5 87.92(18) 
S2−Ru1−Cl1 174.20(3) N4−Ru1−S2 93.4(3) N4−Ru1−S1 174.85(5) N4−Ru1−S1 179.63(13) 
S3−Ru1−Cl1 93.86(3) S1−Ru1−S2 87.66(10) N5−Ru1−S1 96.34(5) N5−Ru1−S1 92.00(14) 
 
RuCl2(DMSO)4 without reflux is similar in this regard.  The three DMSO ligands are in a 
fac- arrangement and bound through the sulfur atoms, indicating that the oxygen-bound 
DMSO of the RuCl2(DMSO)4 is the first to depart during synthesis. Extending the same 
reaction from 4 h to 8 h resulted in the formation of complex 3, having a 4:2 
acetonitrile:DMSO coordination.  This suggests that the remaining chloride ligand on the 
Ru center is the next ligand to depart, along with one of the sulfur-bound DMSO ligands. 
This leaves two DMSO ligands on the Ru center of 3 in a cis arrangement. Complexes 4 
and 5 show more extensive, though still incomplete acetonitrile substitution, and present 
a unique 5:1 acetonitrile:DMSO coordination that, to our knowledge, has not yet been 
structurally characterized for a transition metal center.   
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 In complexes 2, 3, 4, and 5, the angular distortion of the Ru octahedron arises 
from the unsymmetrical ligand coordination (Table 2.4). In 2, Ru-L angles range from 
85.56(8)°-93.86(3)°, and in 3, Ru-L angles range from 83.5(4)° to 96.0(3)°.  Sterics of the 
single bulkier DMSO ligand result in acute cis-N-Ru-N angles (85.37(7)°-90.23(18)°) 
involving the N4 nitrogen (trans to DMSO) in 4 and 5. The trans influence of the DMSO 
ligand also imparts measurable differences in the Ru-N bond distances for the acetonitrile 
ligands (Table 2.4).  This occurs in the Ru-N1 and Ru-N2 interactions of 2 (2.073(3) and 
2.085(3) Å), the Ru-N3 and Ru-N4 interactions (and the equivalent Ru-N bonds on the 
three other unique Ru sites) of 3 (2.101(9) and 2.073(9) Å), and the Ru-N4 interactions of 
4 (2.0765(19) Å) and 5 (2.094(5) Å).  Similar trans effects are observed in other 
ruthenium complexes with acetonitrile and mixed ligands, notably in [Ru(phen-NH-
phen)(NCCH3)(DMSO)] (Ru-N = 2.064 Å) compared to [Ru(phen-NH-phen)(NCCH3)2] 
(Ru-N = 2.026 Å).30 Acetonitrile ligands coordinated to Ru opposite another acetonitrile 
ligand exhibit Ru-N distances similar to those in the hexakis(acetonitrile) complexes 1a 
and 1b where no trans effect is imparted. Typical Ru-Cl (2.4253(8) Å) and Ru-S (ranging 
from 2.2580(14) to 2.2902(8) Å) distances are observed in the complexes in the present 
study.  We do note that the Ru-S bond lengths are all slightly longer in complex 2, with 
three DMSO ligands (ranging from 2.2832(8) to 2.2902(8) Å) compared to those in 
complex 3 having a cis arrangement of two DMSO ligands (2.260(3) to 2.277(3) Å), as 
well as to the single DMSO ligands present in 4 and 5 (2.2580(14) to 2.2621(6) Å).  This 
likely arises due to the steric effects of three DMSO ligands in the fac arrangement in 2, 
as these distances are nearly identical to those in [RuCl2(NCCH3)(DMSO)3],32 also 
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having a fac  arrangement of DMSO ligands. 
 Based on the crystals obtained, several broad observations can be made regarding 
the synthetic approach and the resulting coordination.  Following Scheme 2.1, we 
observe there is a definite sensitivity of complex formation toward the reaction 
conditions.  When treated under mild conditions in acetonitrile, the RuCl2(DMSO)4 
complex reacts to form a Ru complex that retains the three sulfur-bound DMSO ligands 
as well as one of the chloride ligands (2).  The crystallized material of complex 2 proved 
to be a somewhat complicated mixture of the reaction components, but nevertheless the 
reaction is promising for developing a greater variety of targeted coordination patterns 
about Ru(II).  Maintaining the mild conditions (no reflux), but increasing the reaction 
time affords acetonitrile substitution for the remaining chloride ligand and one of the 
DMSO ligands of 2, resulting in 3, the 4:2 acetonitrile:DMSO complex.  When reflux in 
acetonitrile is employed with the RuCl2(DMSO)4 precursor, then the 5:1 
acetonitrile:DMSO complexes were obtained (4 and 5).  Once DMSO has coordinated the 
Ru center of RuCl2(DMSO)4, complete substitution by acetonitrile proves challenging, 
since even after reflux for up to 4 h and crystal growth in acetonitrile, one DMSO ligand 
remains. 
      
2.3 Conclusions 
 The lability of acetonitrile and DMSO ligands makes these ruthenium complexes 
valuable synthons for a variety of ruthenium complexes. [Ru(NCCH3)6][BF4] (1) is an 
excellent starting material to synthesize homoleptic ruthenium complexes. In contrast, 
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complexes 2-5 could be used to synthesize heteroleptic ruthenium complexes, and 
complexes 4 and 5 are the first 5:1 acetonitrile: DMSO Ru(II) complexes. The ease of 
synthesis for these complexes will allow greater entry into the synthesis a variety of 
Ru(II) complexes, including potential  anticancer ruthenium species. 
 
2.4 Experimental Methods  
  General methods. Synthesis of all complexes was performed under argon using 
standard Schlenk techniques except where indicated. Ruthenium(III) chloride hydrate 
(Oakwood), silver nitrate, sodium tetrafluoroborate, hydrochloric acid (20%), and zinc 
powder were used without purification. Acetonitrile, acetone, and ethanol were purified 
by distillation under an argon atmosphere; dimethyl sulfoxide and anhydrous diethyl 
ether were used without further purification. DMSO was dried over 4 Å molecular sieves 
prior to use. RuCl2(DMSO)4 was synthesized as reported by Evans et al. 20. 1H NMR 
spectra were recorded using a 300 MHz Bruker-AVANCE NMR spectrometer and 1H 
NMR chemical shifts are reported in δ relative to tetramethylsilane (δ 0) and referenced 
to solvent (Figures 2.5-2.9).  IR spectra were obtained from Nujol mulls on KBr salt 
plates with a Magna 550 IR spectrometer (Figures 2.10-2.14). MALDI mass spectra were 
obtained using a Bruker Microflex MALDI-TOF mass spectrometer with trans-2-[3-(4-
tert-butylphenyl)-2-methyl-2-propenyldiene]malonitrile (m/z 251.3 for cation with H+) as 
the matrix. All observed peak envelopes match theoretical calculations for their ions 
(2.15-2.18).   
  Synthesis of [Ru(NCCH3)6 ][BF4]2  (1). Synthesis of [Ru(NCCH3)6][BF4]2 was 
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accomplished by modifying the methods reported for the previous syntheses of 
[Ru(NCCH3)6][BF4]2 (1) and Ru(NCCH3)6][ZnCl4] 3,9.   RuCl3·3H2O (261 mg, 1 mmol) 
was dissolved in freshly distilled acetonitrile (25 mL), and zinc powder (65 mg, 1 mmol) 
was added. The reaction mixture was heated to reflux with stirring for 2 h, and the color 
changed from black to yellow during this time. The reaction mixture was then cooled and 
filtered to remove excess zinc. AgNO3 (340 mg, 2 mmol) was added to the filtrate, and 
this mixture was again heated to reflux with stirring for 2 h. A white precipitate formed, 
and the reaction mixture was cooled and filtered. The counterion was exchanged by 
adding NaBF4 (220 mg, 2 mmol) to the filtrate and heating the reaction mixture to reflux 
with stirring for 4 h, resulting in formation of a white precipitate. Again the reaction 
mixture was cooled and filtered; the filtrate was cooled to -20 ̊ C for 15 h and filtered a 
second time to remove any precipitate before the solvent volume was reduced to 10 mL 
in vacuo. Diethyl ether (40 mL) was then added, yielding a white precipitate that was 
recrystallized in acetonitrile to afford the product. Yield: 390 mg (75%). Crystals for X-
ray analysis were grown from vapor diffusion of diethyl ether into a solution of 1 in 
acetonitrile. NMR and IR spectra match previous characterization of 1 3,9. Analysis of 
C12H18B2F8N6Ru, Calcd. (Exp.): C, 27.66 (27.70); H, 3.48 (3.49); N, 16.13 (15.94). 
 Synthesis of [RuCl(NCCH3)2(DMSO)3][BF4]1.5[Cl]0.5[Na] (2). AgNO3 (340 mg, 2 
mmol) was added to a solution of RuCl2(DMSO)4 (484 mg, 1 mmol) in acetonitrile (20 
mL) and stirred for 4 h at room temperature. During this time, a white precipitate formed, 
and the reaction color turned from yellow to colorless. The reaction mixture was filtered, 
and the filtrate was treated with NaBF4 (220 mg, 2 mmol) and stirred for an additional 4 
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h. The reaction mixture was filtered again, and the filtrate solvent was removed in vacuo. 
The resulting white powder was washed with diethyl ether (20 mL) and dried. Vapor 
diffusion of diethyl ether into an acetonitrile solution of 3 was used to grow crystals 
suitable for X-ray analysis.  Yield: 400 mg (65%). 1H NMR (D2O): δ 2.62 (s, 6H, 
CH3CN), 3.49 (s, 12H, DMSO trans to CH3CN), and 3.46 (s, 6H, DMSO trans to Cl). IR 
(Nujol, cm-1): 2300 (w, C≡N), 2332 (w, C≡N), 1121 (S-O), 1067 (S-O). Analysis of 
[Ru(NCCH3)4(DMSO)2][BF4]2 (C12H24B2ClF8N4O2RuS2), Calcd. (Exp.): C, 24.22 
(23.60); H, 4.06 (3.87); N, 9.41 (9.21). MALDI-MS (m/z) = 369 
[RuCl(NCCH3)(DMSO)2+Cl+H]+, 448 [RuCl(NCCH3)(DMSO)3]+Cl+H]+. 
  Synthesis of [Ru(NCCH3)4(DMSO)2][BF4]2 (3). A similar procedure that was 
used to synthesize 2 was used to synthesize 3 except the reaction time was increased to 8 
h at room temperature.   During this time, a white precipitate formed, and the solution 
turned from yellow to colorless. The reaction mixture was filtered, and the filtrate was 
treated with NaBF4 (220 mg, 2 mmol) and stirred for an additional 12 h. The reaction 
mixture was filtered again, and the filtrate solvent was removed in vacuo. The resulting 
white powder was washed with diethyl ether (20 mL) and dried. Vapor diffusion of 
diethyl ether into an acetonitrile solution of 3 was used to grow crystals suitable for X-ray 
analysis.  Yield: 434 mg (73%). 1H NMR (D2O): δ 2.59 (s, 6H, CH3CN), 2.61 (s, 6H, 
CH3CN), 3.46 (s, 12H, DMSO). IR (Nujol, cm-1): 2296 (w, C≡N), 2325 (w, C≡N), 1122 
(S-O), 1070 (S-O). Analysis of [RuCl(NCCH3)2(DMSO)3][BF4]1.5[Cl]0.5[Na]·CH3CN 
(C12H27B1.5Cl1.5F6N3NaO3RuS3), Calcd. (Exp.): C, 24.22 (23.60); H, 4.06 (3.87); N, 9.41 
(9.21). MALDI-MS (m/z) = 386 [Ru(NCCH3)(DMSO)2+BF4]+, 431 
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[Ru(NCCH3)4(DMSO)+BF4]+. 
 Synthesis of [Ru(NCCH3)5(DMSO)][NO3]2 (4). RuCl2(DMSO)4 (484 mg, 1 mmol) 
was treated with (340 mg, 2 mmol) AgNO3 in acetonitrile (30 mL), and the mixture was 
heated to reflux and stirred for 4 h. A white precipitate formed, and the reaction mixture 
turned from yellow to colorless. The reaction mixture was then filtered, the solvent was 
removed in vacuo, and the resulting white powder was washed with diethyl ether (20 mL) 
and dried. Crystals of 4 suitable for X-ray analysis were grown by slow vapor diffusion 
of diethyl ether into acetonitrile. Yield: 410 mg (70%). 1H NMR (D2O): δ 2.53  and 2.55 
(both s, 15H, CH3CN); 3.43 and 3.44 (both s, 6H, DMSO). IR (Nujol, cm-1): 2300 (w, 
C≡N) 2324 (w, C≡N), 1127 (S-O), 1035 (S-O). Analysis of 
[Ru(NCCH3)5(DMSO)][NO3]2.H2O (C12H23N7O8RuS), Calcd. (Exp.): C, 27.38 (27.04); 
H, 4.40 (4.27); N, 18.62 (18.27). MALDI-MS (m/z): 364 [Ru(NCCH3)3(DMSO)+NO3]+, 
408 [Ru(NCCH3)4(DMSO)+NO3]+.  
  Synthesis of [Ru(NCCH3)5(DMSO)][BF4]2 (5). Complex 4 (590 mg, 1 mmol) was 
treated with NaBF4 (220 mg, 2 mmol) in acetonitrile (30 mL), the reaction mixture was 
heated to reflux with stirring for 4 h, and a white precipitate formed. The reaction mixture 
was filtered, and the solvent was removed in vacuo. The resulting white powder was 
washed with diethyl ether (20 mL) and dried to afford 5. Vapor diffusion of diethyl ether 
into an acetonitrile solution 5 was used to grow crystals suitable for X-ray analysis.  
Yield: 440 mg (79%). Elemental analysis showed a 6% NaBF4 impurity from the 
counterion exchange, so the complex was recrystallized in acetonitrile before performing 
additional characterization. 1H NMR (D2O): δ 2.53 and 2.56 (both s, 15H, CH3CN), 3.42 
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and 3.42 (both s, 6H, DMSO). IR spectra (Nujol, cm-1): 2303 (w, C ≡ N), 2324 (w, C ≡ 
N), 1123 (S-O), 1029 (S-O). Analysis of [Ru(NCCH3)5(DMSO)][BF4]2.NCCH3.NaBF4 
(C14H24B3F12N6NaORuS), Calcd.(Exp.): C, 23.72 (23.30); H, 3.41 (3.34); N, 11.85 
(11.56). MALDI-MS (m/z): 281 [Ru(NCCH3)2(DMSO)]+F]+, 321 
[Ru(NCCH3)3(DMSO)]+F]+, 471 [Ru(NCCH3)5(DMSO)+BF4]+. 
  X-ray crystallography. Single crystal X-ray diffraction measurements were 
acquired using two different diffractometers, both equipped with Mo Kα (λ = 0.71073 Å) 
radiation.  Diffraction data at 100 K were measured using a Bruker D8 Venture with an 
Incoatec microfocus source and a Photon 100 CMOS detector.  Room temperature data 
were obtained using a Rigaku AFC8S diffractometer with a sealed glass X-ray tube and a 
Mercury CCD detector.  Instrument control, data processing, and scaling corrections were 
performed using the Apex3 software suite in the case of the Bruker instrument, and the 
CrystalClear software package in the case of the Rigaku instrument 35-36. Space group 
assignments were unambiguously made based on systematic absences.  All structures 
were solved by direct methods and refined to convergence by full-matrix least squares 
using the SHELXTL software suite 37. All non-hydrogen atoms were refined 
anisotropically.  Hydrogen atoms attached to carbon atoms were placed geometrically 
and treated using appropriate riding models.  
 Data from the structure refinements of the resulting ruthenium complexes are 
shown in Tables 2.5-2.7.  Ruthenium atoms were always six-coordinate, but coordinated 
by varying ratios of the ligands.  In several instances the presence of solvent molecules in 
the crystals was deduced from the X-ray data, presumably assisting in the long-range  
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 Table 2.5. Crystallographic data for complexes 1a and 1b. 
 1a 
[Ru(NCCH3)6][BF4]2 
1b 
[Ru(NCCH3)6][BF4]2 
empirical formula C12H18B2F8N6Ru  C12H18B2F8N6Ru  
formula weight (g/mol) 521.01 521.01 
temperature (K) 100 100 
crystal system Monoclinic  Monoclinic 
space group P21/c  C2/m 
unit cell dimensions (Ǻ,⁰) 
a = 8.0927(8) 
b = 8.1321(8) 
c = 15.7736(17) 
β = 93.119(3) 
a = 11.8512(10) 
b = 17.1331(14) 
c = 5.5973(4) 
β = 103.799(2) 
volume (Å3) 1036.53 1103.72 
Z, calcd density (mg/m3) 2, 1.669 2, 1.568 
absorption coefficient (mm-1) 0.836 0.785 
F(000) 516 516 
crystal size (mm) 0.48 x 0.41 x 0.28  0.10 x 0.09 x 0.09 
T max, T min 1.0000, 0.8819 1.0000, 0.9012 
Θ range for data 2.52-36.37 2.13-25.98 
reflns collected/unique/obs. 28908/5024/4289 10432/1125/1124 
data/restraints/parameters 5024/0/136 1125/9/85 
goodness-of-fit on F2 1.180 1.074 
R1, wR2 (I≥ 2σ(I)) 0.0230, 0.0686 0.0296, 0.0809 
R1, wR2 (all data) 0.0302, 0.0794 0.0296, 0.0810 
largest diff.  peak, hole (e/Å3) 0.726, -1.259 0.988, -0.558 
   
 
Table 2.6. Crystallographic data for complexes 2 and 3. 
 
2 
[RuCl(NCCH3)2(DMSO)3] 
[BF4]1.5[Cl]0.5[Na]·xNCCH3 
3 
[Ru(NCCH3)4(DMSO)2] 
[BF4]2·0.5NCCH3 
empirical formula C10H24B1.5Cl1.5F6N2NaO3RuS3 C13H25.5B2F8N4.5O2RuS2 
formula weight (g/mol) 623.94 615.69 
temperature (K) 100 100 
crystal system Orthorhombic Triclinic 
space group Fdd2 P-1 
unit cell dimensions (Ǻ,⁰) 
a = 15.7199(9) 
b = 40.665(2) 
c = 14.8332(8) 
a = 12.8875(10) 
b = 15.1344(12) 
c = 27.244(2) 
α = 101.191(3) 
β = 102.226(3) 
γ = 90.229(4) 
volume (Ǻ3) 9482.1(9) 5088.9(7) 
Z, calcd density (mg/m3) 16, 1.748 8, 1.607 
absorption coefficient (mm-1) 1.174 0.856 
F(000) 4992 2472 
crystal size (mm) 0.39 x 0.16 x 0.08 0.20 x 0.17 x 0.08 
Tmax, Tmin 1.0000, 0.9078 1.0000, 0.8920 
Θ range for data 1.95-33.13 1.94-25.25 
reflns collected/unique/obs. 26136/8037/7643 114946/18357/16257 
data/ restraints/parameters 8037/1/276 18357/0/1206 
goodness-of-fit on F2 1.206 1.153 
R1, wR2 (I≥ 2σ(I)) 0.0245, 0.0628 0.0938, 0.2135 
R1, wR2 (all data) 0.0284, 0.0736 0.1041, 0.2198 
largest diff.  peak, hole (e/Å3) 0.910, -1.131 2.959, -1.455 
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Table 2.7. Crystallographic data for complexes 4 and 5. 
 
4 
[Ru(NCCH3)5(DMSO] 
[NO3]2·2NCCH3 
5 
[Ru(NCCH3)5(DMSO)] 
[BF4]2 
empirical formula C16H27N9O7RuS C12H21B2F8N5ORuS 
formula weight (g/mol) 590.59 558.09 
temperature (K) 100 293 
crystal system Monoclinic Monoclinic 
space group P21/c P21/c 
unit cell dimensions (Ǻ,⁰) 
a = 16.3743(9) 
b = 7.6068(4) 
c = 20.9641(13) 
β = 98.822(2) 
a = 12.8983(14) 
b = 12.4288(13) 
c = 15.5070(18) 
β = 106.081(3) 
volume (Ǻ3) 2580.3(3) 2388.7(5) 
Z, calcd density (mg/m3) 4, 1.520 4, 1.552 
absorption coefficient (mm-1) 0.740 0.817 
F(000) 1208 1112 
crystal size (mm) 0.27 x 0.22 x 0.03 0.47 x 0.35 x 0.29 
Tmax, Tmin 1.0000, 0.9232 1.0000, 0.8900 
Θ range for data 2.49-26.52 2.13-25.25 
reflns collected/unique/obs. 43231/5344/4746 20203/4333/3717 
data/ restraints/parameters 5344/12/316 4333/0/278 
goodness-of-fit on F2 1.040 1.096 
R1, wR2 (I≥ 2σ(I)) 0.0291, 0.0605 0.0681, 0.1896 
R1, wR2 (all data) 0.0352, 0.0630 0.0766, 0.2110 
largest diff.  peak, hole (e/Å3) 1.145, -0.195 1.926, -1.020 
   
 
packing of the target molecules.  These atoms were modeled and refined in the same way 
as the rest of the atoms in the structure, except in the case of complex 2.  Complex 2 
crystallized with highly disordered acetonitrile solvent molecules that were modeled 
using the SQUEEZE algorithm of PLATON (corresponding to approximately 0.66 
C2H3N molecules per formula unit) 38. These crystals also possessed a more complex 
mixture of counterions derived from the reaction mixture including Na+ and Cl- in 
addition to the expected [BF4]- anions.  Crystals of 3 contained 0.5 acetonitrile molecules 
per formula unit.  Crystals of complex 4 contained two molecules of acetonitrile per 
formula unit.  The crystals of complex 3 were always found to be non-merohedrally 
twinned over multiple domains, which ultimately limited the intensities contributed by 
the primary domain and the quality of those refinements.  However, the structural model 
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of 3 is reasonable and consistent with the supporting characterization.  Finally, we note 
that the structure of complex 1a was already reported at 168 K,9 but an improved 
refinement from data collected at 100 K in the course of this study is included for 
completeness and comparative purposes to polymorph 1b. 
 
2.5 Supplemental Material 
 
 
Figure 2.3. Packing diagrams for [Ru(NCCH3)6][BF4]2 polymorphs 1a and 1b as viewed along the c-axis. 
Hydrogen atoms are omitted for clarity. 
 
 
Figure 2.4. X-ray diffraction structure for [Ru(NCCH3)5(DMSO)][BF4]2·2CH3CN (5 with additional lattice 
acetonitrile) with mixed acetonitrile and DMSO coordination.  Atoms are shown as 50% probability 
ellipsoids, and hydrogen atoms, counterions, and solvent molecules are omitted for clarity. 
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Table 2.8. Selected interatomic distances (Å) and angles (°) for [Ru(NCCH3)5(DMSO)][BF4]2·2CH3CN (5 
with additional lattice acetonitrile). 
 [Ru(NCCH3)5(DMSO)][BF4]2 ·2CH3CN 
Ru1−N1 2.042(5) 
Ru1−N2 2.023(5) 
Ru1−N3 2.012(5) 
Ru1−N4 2.101(5) 
Ru1−N5 2.029(5) 
Ru1−S1 2.2580(14) 
N1−Ru1−N2 175.06(18) 
N1−Ru1−N3 87.77(18) 
N1−Ru1−N4 89.14(18) 
N1−Ru1−N5 93.39(18) 
N1−Ru1−S1 91.23(13) 
N2−Ru1−N3 88.55(18) 
N2−Ru1−N4 87.59(18) 
N2−Ru1−N5 90.19(19) 
N2−Ru1−S1 92.05(13) 
N3−Ru1−N4 90.23(18) 
N3−Ru1−N5 177.81(17) 
N3−Ru1−S1 89.83(13) 
N4−Ru1−N5 87.92(18) 
N4−Ru1−S1 179.63(13) 
N5−Ru1−S1 92.00(14) 
 
 
 
Table 2.9. Crystallographic data for [Ru(NCCH3)5(DMSO)][BF4]2·2CH3CN (5 with additional lattice 
acetonitrile). 
 [Ru(NCCH3)5(DMSO)][BF4]2·2NCCH3 
empirical formula C16H27B2F8N7ORuS 
formula weight (g/mol) 640.19 
temperature (K) 293 
crystal system Triclinic 
space group P-1 
unit cell dimensions (Ǻ,⁰) 
a = 10.779(2) 
b = 10.878(2) 
c = 13.416(3) 
α = 101.783(4) 
β = 90.281(5) 
γ = 111.654(3) 
volume (Ǻ3) 1425.7(5) 
Z, calcd density (mg/m3) 2, 1.491 
absorption coefficient (mm-1) 0.697 
F(000) 644 
crystal size (mm) 0.56 x 0.40 x 0.14 
Tmax, Tmin 1.0000, 0.5985 
Θ range for data 2.61-25.15 
reflections collected/unique/observed  9215/4853/4126/ 
data/ restraints/ parameters 4853/0/334 
goodness-of-fit on F2 1.066 
R1, wR2 (I≥ 2σ(I)) 0.0605, 0.1558 
R1, wR2 (all data) 0.0723, 0.1714 
largest diff.  peak, hole (e/Å3) 1.388, -0.880 
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Figure 2.5. 1H NMR spectrum of [Ru(NCCH3)6][BF4]2 (1) in D2O. The resonance at δ 2.12 is from 
unbound CH3CN. 
 
 
 
 
 
Figure 2.6. 1H NMR spectrum of [RuCl(NCCH3)2(DMSO)3][BF4]1.5[Cl]0.5[Na] (2) in D2O.  The resonance 
at δ 2.05 is from unbound acetonitrile, and the resonance at δ 2.71 is from unbound DMSO. 
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Figure 2.7. 1H NMR spectrum of [Ru(NCCH3)4(DMSO)2][BF4]2 (3) in D2O. The resonance at δ 2.10 is 
from unbound acetonitrile, and the resonance at δ 2.52 is [Ru(NCCH3)6][BF4]2. 
 
 
 
 
Figure 2.8. 1H NMR spectrum of [Ru(NCCH3)5(DMSO)][NO3]2 (4) in D2O.  The resonance at δ 2.04 is 
from unbound acetonitrile, and the resonance at δ 3.71 is from unbound DMSO. 
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Figure 2.9. 1H NMR spectrum of [Ru(NCCH3)5(DMSO)][BF4]2 (5) in D2O. The resonance at δ 2.04 is from 
unbound acetonitrile, and the resonance at δ 3.71 is from unbound DMSO. 
 
 
 
 
Figure 2.10. Transmittance IR spectrum of [Ru(NCCH3)6][BF4]2 (1) acquired as a Nujol mull. 
 
 
 
ppm
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Figure 2.11. Transmittance IR spectrum of [Ru Cl(NCCH3)2(DMSO)3][BF4]1.5[Cl]0.5[Na] (2) acquired as a 
Nujol mull. 
 
Figure 2.12. Transmittance IR spectrum of [Ru(NCCH3)4(DMSO)2][BF4]2 (3) acquired as a Nujol mull. 
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Figure 2.13. Transmittance IR spectrum of [Ru(NCCH3)5(DMSO)][NO3]2  (4) acquired as a Nujol mull. 
 
 
 
 
Figure 2.14. Transmittance IR spectrum of [Ru(NCCH3)5(DMSO)][BF4]2  (5) acquired as a Nujol mull. 
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Figure 2.15. MALDI mass spectrum with insets of experimental (left) and simulated (right) envelope 
intensities for [RuCl(NCCH3)2(DMSO)3] [BF4]1.5[Cl]0.5[Na] (2). 
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Figure 2.16. MALDI mass spectrum with insets of experimental (left) and simulated (right) envelope 
intensities for [Ru(NCCH3)4(DMSO)2] [BF4]2 (3). 
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Figure 2.17. MALDI mass spectrum with insets of experimental (left) and simulated (right) peak envelope 
intensities for [Ru(NCCH3)5(DMSO)][NO3]2 (4). 
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Figure 2.18. MALDI mass spectrum with insets of experimental (left) and simulated (right) peak envelope 
intensities for [Ru(NCCH3)5(DMSO)][BF4]2 (5). 
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CHAPTER THREE 
SYNTHESIS, CHARACTERIZATION, AND STUDY OF THE ANTIOXIDANT 
ACTIVITY OF NOVEL RUTHENIUM IMIDAZOLE-2-THIONE AND SELONE 
COMPLEXES 
 
3.1 Introduction 
 Recently, ruthenium complexes with sulfur- and selenium-containing ligands have 
attracted attention for their catalytic1-3 and biological3-10 applications. Ruthenium can 
mimic iron in biological systems because it is redox active and can bind to sulfur in 
biomolecules.11-13 In cells, Fe(II) can generate damaging hydroxyl radical in the presence 
of hydrogen peroxide (Reaction 3.1) that cause oxidative damage and cell death that can  
lead to cancer, cardiovascular diseases, and neurodegenerative diseases.14-18 Ru(II) also 
may generate damaging hydroxyl radical, similar to Fe(II) (Reaction 3.1).19 Some sulfur- 
and selenium-containing compounds can scavenge hydroxyl radical to prevent oxidative 
damage,20-21 and metal coordination can improve this activity.22-26 
Ru(II)/Fe(II) + H2O2 → Ru(III)/Fe(III) + •OH + -OH     (3.1) 
 Cysteine, selenocysteine, ergothioneine, and selenoneine are common biological 
sulfur and selenium compounds (Figure 3.1) that can bind metal ions.  These compounds 
prevent metal-mediated DNA damage by hydroxyl radical, and are widely investigated for 
their roles as antioxidants to prevent diseases caused by oxidative stress.15,18,27-28  In 
particular, imidazole thiones (C=S) and selones (C=Se) are versatile metal-binding ligands 
that have established or emerging biological roles. Ergothioneine prevents copper-
mediated oxidative DNA damage through metal binding29 and also scavenges reactive 
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oxygen species (ROS; Figure 3.1).30-32 Selenoneine is also a potent radical scavenger,33 and 
may help detoxify heavy metals34-37  In addition, imidazole thione and selone compounds 
have pharmaceutical importance as anti-thyroid,38-39 antioxidant26,39 -40 antifungal41 and 
antimicrobial,42 and  compounds. Similar to ergothioneine, the anti-thyroid drug 
methimazole (MMI) as well as the dimethylated dmit and dmise scavenge ROS and prevent 
metal-mediated DNA damage (Figure 3.1).23, 42-46 
N N R
E
 MMI (E = S, R = H)
 dmit (E = S, R = CH3)
 dmise (E = Se, R = CH3)
H3N+ O
EH
O-
O-
O
N+
HHN
N
H
E
E= S; Cysteine
     Se; Selenocysteine
E= S; Ergothioneine
     Se: Selenoneine
 
Figure 3.1. Imidazole thione and selone compounds, derivatives, and their biological forms. 
 
 Although imidazole thione and selone ligands are well known to bind iron and other 
late first-row transition metals,26 only a few ruthenium complexes with imidazole thione 
and selone ligands are known (Figure 3.2).1,47-50 Methimazole binds Ru(II) as a 
monodentate ligand coordinated through the S atom, and when this complex is treated 
with1,47-50 to deprotonate the imidazole nitrogen, methimazole binds as a bidentate ligand 
through the S and aromatic N atoms.47,50 Ru(II) coordination of bidentate thione and selone 
ligands with appended thioether or selenoether groups are also reported (Figure3.2).1,47-50 
N N
E'E
Ru
Cl
E,E' = S,Se or S,S or Se,Se
S
Cl
Ru
PPh3
PPh3
Cl
S N
N
R
S
Ru
PPh3
N
PPh3
N
S
R
N
NH N
H
NR
R
R = Nitro-ph or ph
+
 
Figure 3.2. Reported Ru(II) complexes with imidazole-2-thione and selone ligands (R = alkyl or aryl; E = 
S or Se).1,47 
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      In this work, we present the syntheses of a series of novel homoleptic and heteroleptic 
Ru(III) and Ru(II) thione and selone complexes with the formulae [RuL6]3+, [RuL6]2+, and 
RuL4Cl2 (L = MMI, dmit, and dmise), significantly expanding the  repertoire of known 
ruthenium thione and selone complexes. We also examine hydrogen peroxide reactivity of 
the [RuL6]3+ complexes and the ability of [Ru(MMI)6]3+ to prevent iron-mediated DNA 
damage.  Unlike previous complexes, these Ru(II) complexes allow comparison of the 
effects of multiple ruthenium oxidation states and thione or selone ligands on their 
properties and reactivity. In addition, our methods open the door to synthesize a wide 
variety of ruthenium thione and selone complexes to explore the applications of these 
complexes. 
 
3.2 Results and Discussion 
 Synthesis of Ru(III) thione and selone complexes. Homoleptic [RuL6]Cl3 complexes 
were synthesized by treating RuCl3·3H2O with 6 equiv of MMI (1a), dmit (2), or dmise (3) 
in a 2:1 mixture of methanol/dichloromethane under argon (Scheme 3.1). Selone complex 
3 forms after 3 h, notably faster than formation of thione complexes 1a and 2 (5 h). All 
three complexes were synthesized in good yields (58-69%) and are stable to water and air 
as solids. In acetonitrile solutions, the compounds are stable in air and water for at least    
12 h. 
 To determine whether [Ru(MMI)6]3+ could also be synthesized from a Ru(II) 
starting material, [Ru(NCCH3)6][BF4]2 was treated with 6 equiv MMI in a 2:1 mixture of 
methanol/dichloromethane, and heated to reflux for 4 h under argon, replacing all 
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acetonitrile ligands with MMI ligands (Scheme 3.1). The hot reaction mixture was then 
opened to air and allowed to oxidize (Scheme 3.1), and at the same time, 1 equiv of NaNO3 
was added to provide additional counterions for a Ru(III) species. The resulting 
[Ru(MMI)6][BF4]2[NO3] complex (1b) is formed in a similar yield (65%) as the [RuL6]3+ 
complexes formed from RuCl3·3H2O.  
RuCl3. 3H2O[RuL6]Cl3
RuCl2(DMSO)4
1b (65 %)
[Ru(MMI)6][BF4]2[NO3]
, 4 h
 CH3OH
  CH2Cl2
[Ru(NCCH3)6][BF4]2 , 4 h [RuL6][BF4]2
6 L 6 L
, 4 h
1a, L =  MMI (58%)
2,   L =  dmit (65%)
3,   L =  dmise (69%)
4 L
[RuL4Cl2]
1. 6 MMI
2. NaNO3
7,   L =  MMI (68%)
8,   L =  dmit (72%)
9,   L =  dmise (70%)
Air 4,   L =  MMI (59%)
5,   L =  dmit (64%)
6,   L =  dmise (67%)
ref. 66
ref. 51
 
 
Scheme 3.1. Synthesis of Ru-thione and -selone complexes 1-9. All reactions were carried out in a 2:1 ratio 
of acetonitrile to CH2Cl2. 
 
 Synthesis of Ru(II) thione and selone complexes. Ru(II) analogs of the [RuL6]3+ 
complexes were synthesized under argon by heating a solution of [Ru(NCCH3)6][BF4]2 in   
2:1 methanol/dichloromethane to reflux with 6 equiv of thione or selone ligand to yield 
[Ru(L)6][BF4]2, where L = MMI (4), dmit (5), and dmise (6). Yields of these Ru(II) 
complexes are similar to those of their Ru(III) analogs (59-67%; Scheme 1). Complexes 4, 
5, and 6 are stable under inert atmosphere, both as solids and in organic solvents. Air or 
water exposure results in oxidative decomposition that occurs faster with the dmise 
complex 6 (~ 1 h) than for thione compounds 4 and 5 (~3 h). 
 To obtain heteroleptic Ru(II) solvato complexes with thione and selone ligands, 
Ru(DMSO)4Cl251 (DMSO = dimethylsulfoxide)was treated with 4 equiv of thione or selone 
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compound and heated to reflux for 4 h to yield RuL4Cl2 complexes, where L = MMI (7), 
dmit (8), and dmise (9) (Scheme 3.1).  Air and water stability of compounds 7-9 are similar 
to that of complexes 4-6. Similar to acetonitrile ligands in [Ru(NCCH3)6]2+, DMSO is also 
a photolabile ligand, and Ru(DMSO)4Cl2 has been studied for its antitumor activity as a 
photosentizer for photodynamic therapy.52 Thus, the DMSO ligands on these heteroleptic 
complexes provide additional sites for potential ligand exchange and photoreactivity. 
 MALDI mass spectrometry results (Figures 3.29-3.38) show the molecular ion with 
an associated chloride ion, [Ru(MMI)6]Cl]2+, for 1a, but for 1b, only   
[Ru(MMI)2(BF4)(NO3)]+ with two coordinated MMI ligands is observed.  Similarly, mass 
spectrometry data for Ru(III) complexes 2 and 3 show species with a maximum of two 
thione or selone ligands coordinated: [Ru(dmit)2Cl2]+ and [Ru(dmise)2Cl2]+, respectively.  
For mass spectrometry data of Ru(II) ions 4-6, a maximum of three or four of the six 
thione/selone ligands remained associated to afford  ions with the formulae [Ru(MMI)4F]+, 
[Ru(dmit)4BF4]+, and [Ru(dmise)3(BF4)2H]+, respectively. RuL4Cl2 complexes 7-9 also 
were subject to thione or selone ligand loss under mass spectrometry conditions, yielding 
[RuCl2(MMI)3H]+, [Ru(dmit)2Cl2H]+, and [Ru(dmise)2Cl2H]+ ions, respectively.  Accurate 
elemental analyses were obtained for all ten complexes, indicating that mass spectrometry 
may not be a reliable method to assess thione/selone coordination stoichiometry in these 
complexes.  
      Structural analysis of ruthenium - thione complexes. Single crystals of 1a, 1b, and 5 
were grown by slow diffusion of diethyl ether into acetonitrile solutions of the complexes 
and characterized by X-ray structural analysis. All three complexes have distorted 
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octahedral geometry around the central ruthenium ion (S-Ru-S angles of 84.83(3)-
95.17(3)º for 1a and 86.25(11)-93.75(11)º for 5) and are bound through the sulfur atoms of 
the six thione ligands (Figure 3.3 with bond distances and angles in Table 3.1; the structure 
of 1b and bond lengths and angles are provided in Figure 3.9 and Table 3.5, respectively). 
 Ru-S bond lengths in 1a range from 2.3930(7) to 2.4033(7) Å (and from 2.4010(6)-
2.4155(7) Å in 1b), slightly shorter in average than in 5 (2.403(3)-2.409(3) Å).  The Ru-S 
bond lengths in 5 are similar to those for the reported Ru(II) complexes with two 
monodentate thione ligands, RuL2(PPh3)2Cl2 (Figure 3.2, left), where L = 1-(4-methyl-
phenyl)-imidazole-2-thione (2.478(2)Å47), 1-(4-chlorophenyl)imidazole-2-thione 
(2.4087(15) Å50), or 1,3-dihydrobenzoimidazole-2-thione (2.435(3) Å1).  
 
Figure 3.3. Crystal structure diagrams of A) [Ru(MMI)6]Cl3 (1a) and B) [Ru(dmit)6](BF4)2  (5) with 50% 
probability density ellipsoids. Hydrogen atoms and counterions are omitted for clarity. 
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Table 3.1. Selected bond lengths (Å) and angles (°) for [Ru(MMI)6]Cl3  (1a) and [Ru(dmit)6](BF4)2 (5) and 
unbound thione ligands.   
       1a                   5 MMI53 dmit54 
Ru1—S1 2.4033(7) 2.411(3)   
Ru1—S2 2.4002(7) 2.409(3)   
Ru1—S3 2.3930(7) 2.403(3)   
S1—C1 1.726(3) 1.719(13) 1.685(2) 1.696(5) 
S3—C9 1.717(3) 1.720(15)   
N1-C1 1.345(6) 1.328(16)  1.345(3) 1.349(4)  
N2-C1 1.387(6) 1.379(17) 1.387(4) 1.392(6) 
S3-Ru1-S3 180.0 180.0   
S3-Ru1-S2 95.17(3) 91.80(11)   
S3-Ru1-S2 84.83(3) 88.20(11)   
S3-Ru1-S1 86.55(2) 87.20(11)   
S2-Ru1-S1 90.47(2) 93.75(11)   
S3-Ru1-S1 93.45(2) 92.80(11)   
S2-Ru1-S1 89.53(2) 86.25(11)   
S1-Ru1-S1 180.0 180.0   
            
      C=S bond lengths range from 1.717(3)-1.726(3) Å and 1.718(2)-1.725(2) Å in 1a and 
1b, respectively, whereas in 5, C=S bonds range from 1.719(12)-1.720(15) Å. In all three 
complexes, these bond distances are significantly longer than the C=S bonds in unbound 
methimazole (1.685(2) Å53) or dmit (1.696(5)Å54), respectively. Average N-C bond lengths 
(1.348(4)-1.387(4) Å) for the methimazole ligands in 1a and 1b are similar to those of N-
C bonds in unbound methimazole (1.345(6) and 1.387(4) Å53).  Likewise, N-C bond 
lengths for dmit complex 5 (1.328(16)-1.379(17) Å) are not significantly different from 
those in unbound dmit (1.349(4)-1.392(6) Å54). Lengthening of the C-S bonds upon Ru 
coordination is consistent with metal binding causing an increased contribution from the 
zwitterionic resonance structure of the thione ligand, a trend that is observed for the iron-
thione complexes Fe(dmit)2Cl2 and [Fe(dmit)4][OTf]2.26 
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 Infrared and NMR spectroscopy. All the synthesized ruthenium thione and selone 
complexes (1a, 1b, and 2-9) were characterized using infrared (IR) spectroscopy (Table 
3.2 and Figures 3.18-3.27) to determine the bonding characteristics of the thione and selone 
ligands. Ru-MMI complexes 1a, 1b, 4, and 7 have C=S stretching bands around 1151 cm-1, 
comparable to that for unbound MMI (1150 cm-1).55 Similarly, Ru-coordinated dmise 
ligands in complexes 3, 6, and 9 have C=Se stretching bands from 1150-1152 cm-1, little  
shifted compared to unbound dmise (1147 cm-1).56  Ru-bound dmit ligands in 2, 5, and 8 
have C=S stretching bands ranging from 1171-1172 cm-1, only slightly shifted to lower 
energy compared to unbound dmit (1181 cm-1).57-59 The lack of significant change between 
Ru-bound and unbound MMI and dmise ligands indicate that they are primarily σ- and π-
donors without significant π-acceptor character.   Dmit complexes 2, 5, and 8 show slight 
backbonding interactions, consistent with the longer C=S bonds observed in these  
Table 3.2. C=S/C=Se IR stretches and 1H NMR resonances (in D2O).a 
Compound C=S/C=Se 
(cm-1) 
1H NMR shifts (δ) 
          CH3            Olefinic C-H 
MMI 1150 3.52 6.91, 6.98 
Dmit 1181 3.48 6.95 
Dmise 1147 3.61 7.16 
[Ru(MMI)6]Cl3 (1a) 1151 − − 
[Ru(MMI)6][BF4]2[NO3] (1b) 1151 − − 
[Ru(dmit)6]Cl3 (2) 1171 − − 
[Ru(dmise)6]Cl3 (3) 1150 − − 
[Ru(MMI)6][BF4]2 (4) 1151 3.58 6.95, 7.03 
[Ru(dmit)6][BF4]2   (5) 1171 3.59 7.16 
[Ru(dmise)6][BF4]2  (6) 1152 3.53 6.98 
Ru(MMI)4Cl2 (7) 1151 3.89  7.59, 7.71 
Ru(dmit)4Cl2  (8) 1172        3.76 7.80 
Ru(dmise)4Cl2  (9) 1151        3.72 7.75 
a 1H NMR spectra are not obtainable for Ru(III) complexes. 
 
complexes compared to unbound dmit.  Similar thione and selone bonding behavior was 
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observed for thione and selone complexes of Cu(I/II), Fe(II), and Zn(II).23,26,60-61  No 
differences in ligand donor properties are observed with Ru oxidation state changes, since 
IR stretches of analogous Ru(III) and Ru(II) complexes are identical. 
 For the unbound ligands and the Ru(II) complexes (Table 3.2 and Figures 3.9-3.11), 
1H NMR spectra in D2O were collected immediately after sample preparation; 1H NMR 
spectra of complexes 1a, 1b, and 2-3  are not obtainable due to the paramagnetic properties 
of Ru(III). Upon metal coordination, the N-methyl group resonances for complexes 4-9 
shift slightly downfield from the unbound ligands (Figure 3.12-3.17). 1H NMR data show 
downfield shifts for the olefinic resonances of MMI in 4 (δ 6.95 and 7.03) and dmit in 5 (δ 
7.16) compared to the resonances for unbound MMI (δ 6.91, 6.98), and dmit (δ 6.95). In 
contrast, 1H NMR data show an upfield shift for the olefinic proton resonances of dmise in 
6 (δ 6.98) compared to the resonances of unbound dmise (δ 7.16). This shifting of the 
olefinic proton resonances indicates that Ru(II) binding to MMI or dmit results in an 
increased contribution of the zwitterionic resonance structure (with increased negative 
charge on the sulfur atom and an aromatic imidazole ring) compared to the unbound 
thiones. This trend has been observed previously for iron-thione such as Fe(dmit)2Cl2 and 
[Fe(dmit)4][OTf]2  complexes.23,26,59   
 Similar, but more pronounced downfield shifts upon Ru(II) coordination are 
observed for the olefinic proton resonance shifts are observed for the tetrakis thione/selone 
complexes 7-9 (Table 3.2). Although it may seem that complexes with two Cl- ligands 
would disfavor the thione resonance structure that places more negative charge on the S 
atoms, the greater electron affinity of Cl relative to S suggests that the Cl- ligands stabilize 
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their negative charges better than thione S atoms.  Therefore, while both the chloride and 
sulfur atoms are formally π-donating, the Ru-Cl bonds are more electron withdrawing 
overall than the Ru-S bonds and may favor the zwitterionic resonance structure of the 
thione ligands that places partial negative charges on the sulfur atoms.   
 In contrast, based on NMR shifts, Ru(II) binding to dmise in 6 disfavors this 
zwitterionic resonance structure compared to unbound dmise, a trend that has not been 
reported. The analogous dmit complex 5 shows slight Ru-thione backbonding by IR, 
corroborated by a downfield shift of δ 0.21 the olefinic protons compared to unbound dmit. 
The analogous MMI complex 4 shows little shift in the olefinic resonances (δ 0.04 and 
0.05) compared to unbound MMI. In contrast, the olefinic resonances of 6 show an upfield 
shift of δ 0.18 compared to unbound dmise. RuL4Cl2 complexes 7, 8, and 9 show significant 
downfield shifts of the oelfinic protons (δ 0.68-0.73, 0.85, and 0.59, respectively) 
compared to the corresponding unbound ligands. This unusual effect observed for 6 may 
be a result of six electron-rich dmise ligands coordinating a single Ru(II) ion.  
  UV-vis kinetic studies with H2O2. To examine the potential antioxidant activity of 
the air-stable [RuL6]3+ complexes, UV-vis spectroscopy was used to determine their 
reactivity with hydrogen peroxide. The π- π* transition bands for the Ru-bound thione or 
selone ligands in acetonitrile solutions of 1a, 2, and 3 are observed at 265, 272, and 275 
nm, respectively (spectra for 1a is shown in Figure 3.4, and spectra for 2 and 3 are shown 
in Figures 3.39-3.43). In addition to these UV bands, charge transfer bands are observed 
for complexes 1a and 2 at 683 and 567 nm, respectively, but no charge transfer band 
appears in the visible region for complex 3.  
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Figure 3.4. UV-vis spectra of [Ru(MMI)6]Cl3  (100 μM) in acetonitrile before and after addition of 2 and 
12 equiv H2O2     
 
  
 When acetonitrile solutions of complexes 1a, 2, and 3 are treated with 2 or 12 equiv 
of H2O2, the highly colored Ru(III) solutions lightened significantly over time and brown 
precipitate formed. In the UV-vis spectra, hydrogen peroxide addition reduced the intensity 
of the π- π* transition bands of the imidazole thione or selone ligands, and these bands were 
no longer visible after addition of 12 equiv (Figure 3.4 and Figures 3.44). Disappearance 
of this absorbance band occurred over different times for the different complexes: 1 h for 
MMI complex 1a and dmise complex 3, and 3 h for dmit complex 2.  
 Kinetics of the reactivity of 1a, 2, and 3 with 2 and 12 equiv hydrogen peroxide 
were measured by observing the decrease in the π- π* transition of the thione or selone 
 
Figure 3.5.  Kinetics of [Ru(MMI)6]Cl3 with A) 2 equiv and 12 equiv H2O2, (0-8000 s) and B) The best-fit 
line fit to the initial linear portion of the kinetic curves for 2 equiv and 12 equiv H2O2 (0-100 sec, R2 = 0.991 
and R2 = 0.990, respectively). 
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ligand at λmax values of 265, 272, and 275 nm, respectively. Initial rates were determined 
by the slope of the best-fit line fit to the initial linear portion of the kinetic curves (Figure 
3.5 and Figures 3.43-3.44). For all three complexes, initial rates of reactivity with 2 and 12 
equiv of H2O2 are very similar, indicating the reaction is independent of hydrogen peroxide 
concentration Table 3.3. The rate of H2O2 reactivity for MMI complex 1a was the fastest, 
followed closely by dmise complex 2, and the rate of H2O2 reactivity for dmit complex 2 
was approximately 30 times slower than for 1a or 3.  
Table 3.3. Initial rates for reaction of complexes 1a, 2, and 3 with H2O2. 
Complex Initial rate × 10
-3 (s-1) 
2 equiv H2O2 12 equiv H2O2 
[Ru(MMI)6]Cl3 (1a) 1.0 ± 0.1 1.4 ± 0.1 
[Ru(dmit)6]Cl3 (2) 0.05 ± 0.002 0.05 ± 0.002  
[Ru(dmise)6]Cl3 (3) 1.7 ± 0.1 1.7 ± 0.2 
 
 To determine the products of hydrogen peroxide oxidations, solutions of 1a, 2, and 
3 were combined with 12 equiv H2O2 and allowed to sit for 3 h before the solvent was 
removed in vacuo and the resulting solids were analyzed by MALDI mass spectrometry 
(Figures 3.38-3.43). The positive-ion MALDI mass spectrum of the product that was 
formed from treating [Ru(MMI)6]Cl3 with 12 equiv H2O2 shows formation of the 
methylimidazolium cation (m/z = 84.7) and  [RuCl3H]+ (m/z = 209; Figure 3.38), while 
[SO2H]- (m/z = 64.5),  sulfite [SO3H]- (m/z 80.9), and sulfate [SO4H]- (m/z 96.3) were 
observed in the negative-ion MALDI mass spectrum of the same reaction (Figure 3.39). 
Similar H2O2 reaction products were observed for complexes 2 and 3 (Figures 3.40 and 
43). Based on these observations, Ru-coordinated MMI and dmise much more efficiently 
scavenge H2O2 compared to Ru-bound dmit (Scheme 3.2).                    
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[RuL6]Cl3   + 12 H2O2 RuCl3 + 6 [EO4H]-  +  6 HN N
H
 
Scheme 3.2. Reactivity of [RuL6]Cl3 with H2O2; E = S, L= MMI or dmit; E = Se, L = dmise. 
 
 
 Reactivity of ruthenium-thione/selone complexes with reactive oxygen species 
(ROS) has not been examined, but oxidation of a Ru(II)-bound thiolate ligand in 
[Ru(DPPBT)3]- (DPPBT =  2-(diphenylphosphino)benzene thiolate) to a Ru(III)-bound 
sulfinate ligand was reported upon O2 exposure.  Treating this Ru(III)-sulfinate species 
with hydroxide rapidly reduces it to a Ru(II)-sulfinate complex.62 On the other hand, 
addition of selenious acid to carbon-supported catalysts (Ru/C) increases the catalytic 
activity by selenium prevention of RuO2-film formation.63 Therefore, selenium can react 
with ruthenium metal to form RuSey or RuSeyOx species (where y < 2, x < 2), thereby 
enhancing catalytic activity.63 Uncoordinated thione and selone compounds have been 
widely investigated as antioxidants26,65 and dmit and dmise sacrificially react with two 
equivalents of hydrogen peroxide to yield dimethylimidazolium and S/SeOx species.44  
Ruthenium can bind up to six thione and selone ligands (1a, 2, and 3), potentially enhancing 
the antioxidant activity of imidazole thiones and selones. 
     DNA damage prevention studies. To determine whether the H2O2 reactivity of these 
Ru(III) complexes translates into prevention of biological oxidation, we examined the 
ability of [Ru(MMI)6]Cl3 (3) to prevent oxidative DNA damage.  In this assay, plasmid 
DNA is treated with Fe(II)/H2O2 to generate DNA-damaging hydroxyl radical (Reaction 
1.1) in the presence and absence of 3, since this complex reacts with hydrogen peroxide 
the fastest.  Addition of [Ru(MMI)6]Cl3 in the presence of H2O2 causes no DNA damage 
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(Figure 3.6, lane 3), but Fe(II)/H2O2 causes 86% DNA damage (lane 4). When DNA is 
treated with Fe(II)/H2O2 and increasing concentrations of 3 (0.1-1000 µM; lanes 5-13), 
DNA damage is significantly reduced at low micromolar concentrations, with over 90% 
DNA damage inhibited at 10 µM.  
 Since this Ru(III)-thione complex acts as an antioxidant, the graph of DNA damage 
inhibition vs. complex 3 concentration was fit to a sigmoidal dose-response curve, and the 
concentration at which 3 prevents 50% of the DNA damage (IC50 value) is 1.76 µM (Figure 
3.7).  This IC50 value for 3 is 3.28 fold lower than for prevention of Fe(II)/H2O2-mediated 
DNA damage by MMI alone (IC50 = 5.78 ± 0.07 µM65). Thus, Ru-MMI coordination  
 
Figure 3.6. Gel electrophoresis image of iron-mediated DNA damage prevention by [Ru(MMI)6]Cl3. Lanes 
are MW: 1 kb molecular weight marker; lane 1: plasmid DNA (p); lane 2: p + H2O2 (50 µM); lane 3: p + 
1000 μM [Ru(MMI)6]Cl3 + H2O2; lane 4: p + Fe2+ (2 µM) + H2O2; lanes 5-14: p + Fe2+ + H2O2 + 0.001, 0.01, 
0.1, 1, 10, 50, 100, 500, and 1000 µM [Ru(MMI)6]Cl3, respectively. 
 
 
Figure 3.7 Graph of oxidative DNA damage prevention by [Ru(MMI)6]Cl3 showing the best-fit dose 
response curve with a calculated IC50 value of 1.76 ± 0.01 μM. 
 
[Ru(MMI)6]Cl3 
  
 
 
Damaged DNA 
Undamaged DNA 
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increases the efficacy of MMI as an antioxidant, most likely by increasing the local MMI 
concentration. As a result, the synthesized ruthenium thione and selone complexes not only 
exhibit interesting coordination chemistry, but also demonstrate that metal binding can 
directly enhance thione antioxidant activity. 
 
3.3 Conclusions 
 In summary, ten novel homoleptic or heteroleptic Ru(II/III) thione and selone 
complexes were synthesized and fully characterized, representing the first ruthenium 
complexes with more than two thione or selone ligands.  In addition, the [RuL6]3+ 
complexes 1a, 2, and 3 react to scavenge H2O2, and this scavenging ability likely 
contributes to the ability of [Ru(MMI)6]3+ (3) to prevent oxidative DNA damage more 
effectively than MMI alone.  This work represents a substantial advance in understanding 
the coordination properties and reactivity of thione and selone complexes, and opens up 
new directions to explore metal-modulated antioxidant behavior.  
3.4 Experimental methods 
 General methods. Synthesis of all complexes was performed under argon using 
standard air-sensitive Schlenk techniques except where indicated. Ruthenium(III) chloride 
hydrate (Oakwood) and methimazole (BDH) were used without purification. 
RuCl2(DMSO)4,51 [Ru(NCCH3)6][BF4]2,66 1,3-dimethyl-2-imidazolethione (dmit)39 and 
1,3-dimethyl-2-imidazoleselone (dmise)39 were synthesized as reported. Acetonitrile, 
dichloromethane and methanol were purified by distillation under an argon atmosphere, 
and anhydrous diethyl ether (BDH) was used without further purification.  
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 1H NMR spectra were recorded using a 300 MHz Bruker-AVANCE NMR 
spectrometer; 1H NMR chemical shifts are reported in δ relative to tetramethylsilane (δ 0) 
and referenced to solvent. 1H NMR spectra of ruthenium complexes 4-9 in D2O (referenced 
to (δ 4.7967) are provided in Figures 3.12-3.17.  IR spectra were obtained from Nujol mulls 
on KBr salt plates with a Magna 550 IR spectrometer (spectra for all complexes are 
provided in Figures 3.18-3.27). Vibrational data are described using the abbreviations: vs, 
very strong; s, strong; m, medium; w, weak; b, broad.  
 MALDI mass spectra were obtained using a Bruker Microflex MALDI-TOF mass 
spectrometer with trans-2-[3-(4-tert-butylphenyl)-2-methyl-2-propenyldiene] malonitrile 
(m/z = 251 for cation with H+) as the matrix.  Samples were spotted as acetonitrile solutions, 
and data were collected with laser intensities of 27-33%.  All observed peak envelopes 
match theoretical calculations68 or their ions within the accuracy of the callibration (± 1 
m/z; Figures 3.28-3.37).  UV-vis spectra were obtained using a Shimadzu UV-3101 PC 
spectrophotometer in quartz cuvettes with a 1 cm path length (spectra for complexes 1a, 2, 
and 3 are provided in Figures 3.4 and 3.44).  
 Synthesis of [Ru(MMI)6]Cl3 (1a). Methimazole (MMI; 6 mmol, 684 mg) was 
dissolved in dichloromethane (15 mL) and added to a solution of RuCl3·3H2O (1 mmol, 
261 mg) in methanol (30 mL). The reaction mixture was stirred for 4 h at room temperature. 
The solvent was removed in vacuo, and the resulting dark-blue powder was washed with 
diethyl ether (2 × 20 mL) and recrystallized at least twice by diethyl ether diffusion into an 
acetonitrile solution of the product. Yield: 556 mg, 58%. Crystals for X-ray analysis were 
grown from vapor diffusion of diethyl ether into a solution of 1a in acetonitrile. IR (Nujol, 
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cm-1): 3413 (b), 3109 (w), 2923 (b), 2816 (b), 2733 (w), 1643 (w), 1567 (s), 1455 (s), 1377 
(s), 1316 (w), 1283 (m), 1151 (s), 1101 (m), 918 (w), 853(w), 724 (b,s) 677 (m), 500(w), 
411 (w). Analysis of C24H36Cl3N12RuS6∙4HCl: Calcd. (Exp.): C, 27.76 (28.00); H, 3.88 
(3.86); N, 16.19 (15.89). MALDI-MS (m/z) = 409, [Ru(MMI)6]Cl]2+. UV-vis λmax 
(CH3CN): 265 nm. 
 Synthesis of [Ru(MMI)6][BF4]2[NO3] (1b). Methimazole (6 mmol, 684 mg) 
dissolved in dichloromethane (15 mL) was added via cannula to a solution of 
[Ru(NCCH3)6][BF4]2 (1 mmol, 521 mg) in methanol (30 mL). Then the reaction mixture 
was heated to reflux with stirring for 4 h. The hot, pale blue solution was exposed to air 
and turned dark blue with stirring for 30 min NaNO3 (1 mmol, 84 mg) was added to this 
solution with stirring in air for 1 h. The reaction mixture was filtered, then the solvent was 
removed in vacuo, and the resulting dark-blue powder was washed with diethyl ether (2 × 
20 mL) and recrystallized in acetonitrile at -20 ºC for at least 6 h.  The precipitate was 
filtered, and the filtrate was dried in vacuo to afford product. Yield: 626 mg, 65%. The 
resulting dark-blue powder was washed with diethyl ether (2 × 20 mL) and recrystallized 
at least twice by diethyl ether diffusion into an acetonitrile solution of the product. Crystals 
for X-ray analysis were grown from vapor diffusion of diethyl ether into a solution of 1b 
in acetonitrile. IR (Nujol, cm-1): 3410 (b), 3105 (w), 2920 (b), 2819 (b), 2736 (w), 1568 
(s), 1462 (s), 1378 (s), 1317 (w), 1283 (m), 1151 (s), 1089 (m), 919 (w), 788(w), 724 (b,s), 
677 (m), 500(w), 410 (w). Analysis of C24H36 B2F8N13O3RuS6∙3CH3OH∙H2O: Calcd. 
(Exp.): C, 28.54 (28.55); H, 4.44 (4.64); N, 16.03 (16.49). MALDI-MS (m/z) = 478 
[Ru(MMI)2(BF4)(NO3)]+. 
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 Synthesis of [Ru(dmit)6]Cl3 (2). Synthesis of 2 was carried out using the procedure 
described for 1a, except that dmit (6 mmol, 769 mg) was used in place of methimazole.  
The resulting dark-purple solid was purified as described for 1a. Yield: 635 mg, 65%. IR 
(Nujol, cm-1): 3432 (b), 3177 (w)  3111 (s) 2922 (s), 2811 (s),  2716 (w), 1728 (w), 1563 
(s), 1456 (s), 1378 (s), 1250 (w), 1171 (s), 1095 (s), 1046 (s), 1016 (w), 856 (w), 745 (s), 
679 (s), 582 (w), 501 (w). Analysis of C30H48Cl3N12RuS6∙2H2O: Calcd. (Exp.): C, 35.58 
(35.51); H, 5.18 (5.09); N, 16.60 (16.56).  MALDI, (m/z) = 428, [Ru(dmit)2Cl2]+. UV-vis 
λmax (CH3CN): 272 nm. 
 Synthesis of [Ru(dmise)6]Cl3 (3). Synthesis of 3 was carried out using the procedure 
described for 1a except that dmise (6 mmol, 1051 mg) was added in place of methimazole. 
The resulting dark-brown powder was purified as described for 1a. Yield: 868 mg, 69%. 
IR (Nujol, cm-1): 3405 (b), 3099 (w), 2920 (s), 2801 (s),  2708 (w), 1568 (s), 1462 (s), 1378 
(s), 1317 (s), 1283 (s), 1150 (s), 1089 (s), 919 (s), 788 (s), 724 (s), 677 (s),  489 (s). Analysis 
of C30H48Cl3N12RuSe6∙3CH3CN∙2HCl): Calcd. (Exp.): 30.53 (30.36); H, 4.18(4.21); N, 
15.00 (15.75). MALDI-MS (m/z) = 522, [Ru(dmise)2Cl2]+. UV-vis λmax (CH3CN): 275 nm. 
 Synthesis of [Ru(MMI)6][BF4]2 (4). To a solution of [Ru(NCCH3)6][BF4]2 (1 mmol, 
521 mg) dissolved in methanol (30 mL), a solution of methimazole (MMI; 6 mmol, 684 
mg) dissolved in dichloromethane (15 mL) was added via cannula. The reaction mixture 
was heated to reflux with stirring for 4 h, the reaction was cooled to room temperature, and 
the solvent was removed in vacuo. The resulting greenish powder was purified as described 
for 1b. Yield: 566 mg, 59%. 1H NMR (D2O): δ 3.58 (3H), 6.95 (1H), and 7.03 (1H). IR 
(Nujol, cm-1): 3429 (b), 3101 (w), 2925 (b), 2814 (b), 2737 (w), 1568 (s), 1460 (s), 1378 
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(s), 1282 (m), 1151 (s), 1084 (m), 918 (w), 852(w), 724 (b,s), 675 (m), 503(w), 412 (w). 
Analysis of (C24H36B2F8N12RuS6∙4H2O) Calcd. (Exp.): C, 27.94 (27.93); H, 4.28 (4.05); 
N, 16.26 (15.56). MALDI-MS (m/z) = 577 [Ru(MMI)4F]+  and 778 
[Ru(MMI)4(BF4)(F)H]+.  
 Synthesis of [Ru(dmit)6][BF4]2 (5). Synthesis of 5 was carried out using the 
procedure described for 4 except that dmit (6 mmol, 769.2 mg) was added in place of 
methimazole. The resulting blue powder was purified as described for 1b. Yield: 668 mg, 
64%. 1H NMR (D2O): δ 3.53 (3H) and δ 7.12 (2H). IR (Nujol, cm-1): 3411 (b), 3181 (w), 
3103 (w), 2920 (s), 2807 (s),  2710 (w), 1663 (w), 1564 (s), 1463 (s), 1378 (s), 1239 (s), 
1171 (s), 1101 (w), 1057 (s,b), 749 (s), 731 (s), 663 (s), 594 (s), 517 (s). Analysis of C30H48 
B2F8N12RuS6∙2CH3CN: Calcd. (Exp.): C, 36.27 (36.34); H, 4.83 (4.95); N, 17.42 (17.74). 
MALDI-MS (m/z) = 701, [Ru(dmit)4BF4]+.  
 Synthesis of [Ru(dmise)6][BF4]2 (6). Synthesis of 6 was carried out using the 
procedure described for 4 except that dmise (6 mmol, 1051 mg) was added in place of 
methimazole. The resulting brownish powder was purified as described for 1b. Yield: 887, 
67%. 1H NMR (D2O): δ 3.59 (3H) and δ 7.33 (2H). IR (Nujol, cm-1): 3382 (b),  3107 (vw), 
2932 (s,b), 2824 (s),  2713 (w), 1639 (s), 1491 (s), 1379 (s), 1233 (s), 1152 (m), 1082 (s), 
914 (w), 809 (w), 738 (s), 729 (s), 662 (s), 622 (m),  492 (w). Analysis of 
C30H48B2F8N12RuS6∙4CH3CN: Calcd. (Exp.): C, 30.62 (30.15); H, 4.06 (4.07); N, 15.03 
(15.72). MALDI-MS (m/z) = 801, [Ru(dmise)3(BF4)2H]+. 
 Synthesis of Ru(MMI)4Cl2 (7). To a solution of Ru(DMSO)4Cl2 (484 mg, 1 mmol) 
in methanol (30 mL), a solution of methimazole (MMI; 4 mmol, 456 mg) in 
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dichloromethane (15 mL) was added via cannula. The mixture reaction was heated to reflux 
with stirring for 4 h and then cooled to room temperature. The solvent was removed in 
vacuo, and the resulting greenish powder was purified as described for 1b. Yield: 427 mg, 
68%. 1H NMR (D2O): δ 3.89 (3H), 7.59 (1H), and 7.71 (1H).  IR (Nujol, cm-1): 3427 (b), 
3110 (w), 2923 (b), 2819 (b), 2728 (w), 1643 (w), 1567 (s), 1455 (s), 1377 (s), 1316 (w), 
1283 (m), 1151 (s), 1100 (m), 918 (w), 852(w), 724 (b,s) 678 (m), 500(w), 409 (w). 
Analysis of C16H24 Cl2N8RuS4∙2HCl: Calcd. (Exp.): C, 27.39 (27.25); H, 3.74 (3.85); N, 
15.96 (15.48). MALDI-MS (m/z) = 515, [RuCl2(MMI)3H]+.  
 Synthesis of Ru(dmit)4Cl2 (8). Synthesis of 8 was carried out using the procedure 
described for 7 except that dmit (4 mmol, 513 mg) was added in place of methimazole. The 
resulting brown powder was purified as described for 1b. Yield: 443 mg; 72%. 1H NMR 
(D2O): δ 3.76 (3H) and δ 7.80 (2H). IR (Nujol, cm-1): 3414 (b), 3190 (w), 3101 (w), 2922 
(s), 2809 (s),  2712 (w), 1728 (w), 1563 (s), 1463 (s), 1378 (s), 1249 (m), 1172 (s), 1095 
(w), 1046 (s), 745 (s), 679 (s), 618 (s), 582 (s), 511 (w). Analysis of C30H48 
B2F8N12RuS6∙2CH3CN): Calcd. (Exp.): C, 35.03 (34.39); H, 4.67 (4.70); N, 16.37 (16.78). 
MALDI-MS (m/z) = 393, [Ru(dmit)2Cl]+; 429, [Ru(dmit)2Cl2H]+.  
 Synthesis of Ru(dmise)4Cl2 (9). Synthesis of 9 was carried out using the procedure 
described for 7 except that dmise (6 mmol, 1051 mg) was added in place of methimazole. 
The resulting brown powder was purified as described for 1b. Yield: 610 mg, 70%. 1H 
NMR (D2O): δ 3.59 (3H) and δ 7.33 (2H). IR (Nujol, cm-1): 3409 (b),  3091 (vw), 2916 
(s,b), 2804 (s),  2716 (w), 1646 (w), 1562 (s), 1461 (s), 1378 (s), 1240 (s), 1151 (s), 1092 
(s), 915 (w), 804 (w), 738 (s), 723 (s), 662 (s), 617 (m),  470 (w). Analysis of 
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C30H48B2F8N12RuS6∙4CH3CN: Calcd. (Exp.): C, 28.20 (28.62); H, 4.36 (4.41); N, 11.97 
(12.15). MALDI-MS (m/z) = 523, [Ru(dmise)2Cl2H]+. 
  
      X-ray crystallography. Complexes 1a, 1b, and 5 were characterized by X-ray structural 
analysis. Single crystals of 1a, 1b, and 5 were grown via slow diffusion of diethyl ether 
into acetonitrile solutions. Diffraction data were collected using a Bruker D8 Venture with 
an incoatec microfocus source (Mo Kα, λ = 0.71073 Å) and a Photon 100 CMOS detector.  
Data were processed and corrected for absorption using the Apex 3 software suite, and the 
structures were subsequently solved and refined by least squares techniques on F2 using 
the SHELXTL suite.   In 1a, four molecules of H2O (likely from humid ambient 
atmosphere) per formula unit were found to occupy void space between the ruthenium 
complex and chloride anions, and these solvent molecules were included in the refinement 
model.  In the case of 1b, 1.5 molecules of acetonitrile were present as a solvate in the 
crystal structure, and these were included in the structure refinement.  X-ray structural 
analysis data of complexes 1 and 5 are shown in Table 3.4, and data for 1b are shown in 
Table 3.6. 
 Reactivity of [Ru(MMI)6]Cl3  (1a) with H2O2. In air, [Ru(MMI)6]Cl3 (8.9 mg, 0.1 
mmol) was dissolved in acetonitrile (10 mL) and treated with 2 or 12 equiv of H2O2 (15 
and 90 μL, respectively, of a 9.77 M solution in water). Immediately upon addition of 
H2O2, the color of the reaction mixture started to turn from dark blue to pale brown, and a 
dark brown precipitate formed. After stirring for 1 h, the reaction mixture was dried in 
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vacuo. MALDI-MS (positive ionization, m/z): 84 [C4H6N2]+, 209 [RuCl3H]+; (negative 
ionization; m/z) = 97 [SO4H]-, 80.9 [SO3H]-, 65 [SO2H]-.  
Table 3.4. Crystallographic data for complexes 1 and 5.  
         1a 
[Ru(MMI)6]Cl3 · 4H2O 
             5 
[Ru(dmit)6](BF4)2 
Empirical formula C24H44Cl3N12O4RuS6 C30H48B2F8N12RuS6 
Formula weight (g/mol) 964.49 1043.85  
Temperature (K) 100 147(2)  
Crystal system Triclinic monoclinic 
Space group P-1 C2/c 
Unit cell dimensions (Å,°) a = 9.4451(8) 
b = 10.0437(8) 
c = 11.1320(10) 
a = 15.952(3)   
b = 15.238(3)   
c = 20.460(4)  
volume (Å3) 1022.37(15) 4972.8(16) 
Z, calcd density (g/cm3) 1.567 1.394 g/cm3 
absorption coefficient (mm-1) 0.933 0.633 
F(000) 495 2136 
crystal size (mm) 0.053 × 0.089 × 0.141 0.057 × 0.062 × 0.109 
mm 
T max, T min 1.0000 and 0.9417 1.0000 and 0.8253 
Θ range for data (°) 2.17 to -27.16 3.21 to 25.25 
Reflns collected/unique/obs. 54423 24939 
Data/restraints/parameters 4531 /12/249 4202 / 64 / 323 
Goodness-of-fit on F2 1.077 1.061 
R1, wR2 (I ≥ 2σ(I)) 0.0368, 0.0931 0.1187, 0.2743 
R1, wR2 (all data) 0.0430, 0.0972 0.1621, 0.2975 
Largest diff.  peak, hole (e/Å3) 1.529, -0.841 1.096 and -0.849 
 
       
 Reactivity of [Ru(dmit)6]Cl3 (2) with H2O2. Oxidation studies of [Ru(dmit)6]Cl3 
were carried out as for [Ru(MMI)6]Cl3 oxidation studies, except that [Ru(dmit)6]Cl3 (9.7 
mg, 0.1 mmol) was added in place of [Ru(MMI)6]Cl3. After 50 min, the reaction mixture 
started to turn from dark purple to pale brown, and a dark brown precipitate formed. After 
stirring for 4 h, the reaction mixture was dried in vacuo. MALDI-MS (positive ionization; 
m/z): 97 [C5H8N2]+, 209 [RuCl3H]+, (negative ionization; m/z): 97 [SO4H]-, 81 [SO3H]-,  65 
[SO2H]-. 
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 Reactivity of [Ru(dmise)6]Cl3 (3) with H2O2.  Oxidation studies of [Ru(dmse)6]Cl3 
were carried out as for [Ru(MMI)6]Cl3 oxidation studies, except that [Ru(dmise)6]Cl3 
(12.57 mg, 0.1 mmol) was added in place of [Ru(MMI)6]Cl3. Immediately after H2O2 
addition, the reaction mixture started to turn from dark brown to colorless, and a dark 
brown precipitate formed. After stirring for 1 h, the reaction mixture was dried in vacuo. 
MALDI-MS (positive ionization; m/z) = 97 [C5H8N2]+, 209 [RuCl3H]+, (negative 
ionization; m/z) = 144, [SeO4H]-; 111, [SeO2H]-. 
 UV-vis kinetics studies with H2O2. In air, acetonitile solutions of 1a, 2, and 3 (100 
µM) were prepared, treated with 2 or 12 equiv of H2O2 (15 and 90 μL, respectively, of a 
30% solution (9.77 M) in water), and quickly inverted to mix. Kinetic spectra were 
measured immediately after H2O2 addition at a λmax of 265 nm for [Ru(MMI)6]Cl3 (8000 
s), 272 nm for [Ru(dmit)6]Cl3 (12000 s), and 275 nm for [Ru(dmise)6]Cl3 (8000 s).  For all 
three samples, a final spectrum was acquired at the conclusion of the kinetics studies. 
 Plasmid transfection, amplification, and purification. Plasmid DNA (pBSSK; 3 μL, 
1 pmol) was purified from DH1 E. coli competent cells using ZyppyTM Plasmid Miniprep 
Kit (400 count, Zymo Research). Tris-EDTA buffer (pH 8.01) was used to elute the 
plasmid from the spin columns. Plasmid DNA was dialyzed against 130 mM NaCl for 24 
h at 4°C to ensure all Tris-EDTA buffer and metal contaminates were removed. Plasmid 
concentration was determined by UV-vis spectroscopy at a wavelength of 260 nm. Organic 
and protein contents were also determined using UV-vis spectroscopy from ratios of 
A250/A260 ≤ 0.95 and A260/A280 ≥ 1.8 respectively. Purity was determined through digestion 
of plasmid with Sac1 and Kpn1 in NEB buffer with bovine serum albumin was conducted 
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at 37°C for 90 min. Comparison to an undigested plasmid sample and a 1 kb molecular-
weight marker was conducted by gel electrophoresis. 
 Plasmid DNA damage inhibition assays. Gel electrophoresis samples were 
prepared in deionized H2O, MES buffer (10 mM, pH 6), NaCl (130 mM), 100% ethanol 
(10 mM), FeSO4 (2 µM) and indicated concentrations of [Ru(MMI)6]Cl3 in water were 
combined in a microcentrifuge tube and allowed to stand for 5 min at room temperature. 
Plasmid (pBSSK; 0.1 pmol in 130 mmol NaCl solution) was then added to the reaction 
mixture and allowed to stand for 5 min at room temperature. Hydrogen peroxide (50 μM) 
was added to the indicated lanes and allowed to react at room temperature for 30 min, then 
EDTA (50 μM) was added to quench the reaction and loading dye (2 μL) was added. All 
given concentrations are final concentrations in a 12 μL volume. Samples were loaded into 
a 1% agarose gel in TAE running buffer; and damaged and undamaged plasmid DNA was 
separated by electrophoresis (140 V for 30 min). Gels were then stained using ethidium 
bromide and washed with diH2O before being imaged under UV light. The amounts of 
nicked (damaged) and circular (undamaged) DNA were quantified using UViProMW 
(Jencons Scientific Inc.). The intensity of the circular plasmid band was multiplied by 1.24, 
due to the different binding abilities of ethidium bromide to supercoiled and nicked plasmid 
DNA.69-70 Intensities of the nicked and supercoiled bands were normalized for each lane 
so that % nicked + % supercoiled = 100%. All percentages were corrected for residual 
nicked DNA prior to calculation. Results were obtained in triplicate for all experiments, 
and standard deviations are represented as error bars. Statistical significance was 
determined by calculating p values at 95% confidence (p < 0.05 indicates significance) as 
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described by Perkowski, et al.71 
 Calculation of percent DNA damage inhibition and IC50 value determination. The 
formula 1-[%N-%B]*100 was used to calculate percent DNA damage inhibition; %N = 
percent of nicked DNA in lanes 5-13, and %B = the percent of nicked DNA in the 
Fe2+/H2O2 control lanes. Percentages were corrected for residual nicked DNA (lane 2) prior 
to calculations. Results were obtained from an average of three trials, with indicated 
standard deviations. A plot of percent inhibition of DNA damage versus log concentration 
of [Ru(MMI)6]Cl3 was fit to a variable-slope sigmoidal dose-response curve using 
SigmaPlot, version 11 (Systat Software, Inc.). IC50 value errors were calculated from error 
propagation of the gel electrophoresis measurements. DNA damage prevention studies 
were performed by Andrea Gaertner in the Department of Chemistry at Clemson 
University.  
 
3.5 Supplemental Material 
 
Figure 3.8. Crystal structure of the ruthenium complex in [Ru(MMI)6](BF4)2(NO3)·1.5(C2H3N) (1b) with 
50% probability density ellipsoids; hydrogen atoms, counterions, and solvent molecules omitted for clarity. 
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Table 3.5. Selected interatomic distances (Å) and angles (°) for [Ru(MMI)6](BF4)2 (NO3)·1.5(C2H3N) (1b). 
    1b 
Ru1-S1 2.4142(6) 
Ru1-S2 2.4155(6) 
Ru1-S3 2.4010(6) 
S1-C1 1.719(2) 
S3-C9 1.725(2) 
S3-Ru1-S3 180.0 
S3-Ru1-S2 92.91(2) 
S3-Ru1-S2 87.09(2) 
S3-Ru1-S1 83.54(2) 
S2-Ru1-S1 94.19(2) 
S3-Ru1-S1 96.46(2) 
S2-Ru1-S1 85.81(2) 
S1-Ru1-S1 180.0 
Table 3.6. Crystallographic data for [Ru(MMI)6](BF4)2(NO3)·1.5(C2H3N) (1b). 
 1b 
Empirical formula C27H40.50B2F8N14.50O3RuS6 
Formula weight (g/mol) 1083.29 
Ttemperature (K) 100 
Crystal system Triclinic 
Space group P-1
Unit cell dimensions (Å,º) 
a = 10.6424(9)
b = 13.0583(13)
c = 17.1260(16)
Volume (Å3) 1022.37(15)
Z, calcd density (g/cm3) 2
Absorption coefficient (mm-1) 0.721
F(000) 1100
Crystal size (mm) 0.021 × 0.076 × 0.167
Tmax, Tmin 1.0000, 0.9612
Θ range for data (º) 2.03-26.00
Reflections collected/unique/observed 104786
Data/restraints/parameters 8681/3/579
Goodness-of-fit on F2 1.173
R1, wR2 (I ≥ 2σ(I)) 0.0278, 0.0732
R1, wR2 (all data) 0.0351, 0.0854
Largest diff. peak, hole (e/Å3) 1.055, -0.584
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Figure 3.9. 1H NMR spectrum of unbound methimazole (MMI) in D2O (δ 4.79). 
Figure 3.10. 1H NMR spectrum of unbound N,N’-dimethylimidazole-2-thione (dmit) in D2O (δ 4.79). 
Figure 3.11. 1H NMR spectrum of unbound N,N’-dimethylimidazole-2-selone (dmise) in D2O (δ 4.79). 
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Figure 3.12. 1H NMR spectrum of [Ru(MMI)6][BF4]2 (4) in D2O (δ 4.79). 
 
 
Figure 3.13. 1H NMR spectrum of [Ru(dmit)6][BF4]2 (5) in D2O (δ 4.79). 
 
 
 
Figure 3.14. 1H NMR spectrum of [Ru(dmise)6][BF4]2 (6) in D2O (δ 4.79). 
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Figure 3.15. 1H NMR spectrum of Ru(MMI)4Cl2 (7) in D2O (δ 4.79). 
 
 
 
Figure 3.16. 1H NMR spectrum of Ru Cl2(dmit)4 (8) in D2O (δ 4.79). 
 
 
 
Figure 3.17. 1H NMR spectrum of RuCl2(dmise)4 (9) in D2O (δ 4.79). 
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Figure 3.18. Transmittance IR spectrum of [Ru(MMI)6]Cl3 (1a) acquired as a Nujol mull. 
 
 
 
 
Figure 3.19. Transmittance IR spectrum of [Ru(MMI)6][BF4]2 [NO3] (1b) acquired as a Nujol mull. 
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Figure 3.20. Transmittance IR spectrum of [Ru(dmit)6]Cl3 (2) acquired as a Nujol mull. 
 
 
 
 
 
Figure 3.21. Transmittance IR spectrum of [Ru(dmise)6]Cl3 (3) acquired as a Nujol mull. 
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Figure 3.22. Transmittance IR spectrum of [Ru(MMI)6][BF4]2 (4) acquired as a Nujol mull. 
 
 
 
Figure 3.23. Transmittance IR spectrum of [Ru(dmit)6][BF4]2 (5) acquired as a Nujol mull. 
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Figure 3.24. Transmittance IR spectrum of [Ru(dmise)6][BF4]2 (6) acquired as a Nujol mull. 
 
 
 
Figure 3.25. Transmittance IR spectrum of RuCl2(MMI)4 (7) acquired as a Nujol mull. 
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Figure 3.26. Transmittance IR spectrum of RuCl2(dmit)4 (8) acquired as a Nujol mull. 
 
 
 
Figure 3.27. Transmittance IR spectrum RuCl2(dmise)4 (9) acquired as a Nujol mull. 
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Figure 3.28. MALDI mass spectrum with insets of experimental (left) and simulated (right) envelope 
intensities for [Ru(MMI)6]Cl3 (1a).  
 
 
 
Figure 3.29. MALDI mass spectrum with insets of experimental (left) and simulated (right) envelope 
intensities for [Ru(MMI)6](BF4)2(NO3) (1b). 
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Figure 3.30. MALDI mass spectrum with insets of experimental (left) and simulated (right) envelope 
intensities for [Ru(dmit)6]Cl3 (2). 
 
 
 
Figure 3.31. MALDI mass spectrum with insets of experimental (left) and simulated (right) envelope 
intensities for [Ru(dmise)6]Cl3 (3). 
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Figure 3.32. MALDI mass spectrum with insets of experimental (left) and simulated (right) envelope 
intensities for [Ru(MMI)6][BF4]2 (4). 
 
 
 
Figure 3.33. MALDI mass spectrum with insets of experimental (left) and simulated (right) envelope 
intensities for [Ru(dmit)6][BF4]2 (5). 
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Figure 3.34. MALDI mass spectrum with insets of experimental (left) and simulated (right) envelope intensities for 
[Ru(dmise)6][BF4]2 (6). 
 
 
 
 
Figure 3.35. MALDI mass spectrum with insets of experimental (left) and simulated (right) envelope 
intensities for RuCl2(MMI)4 (7). 
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Figure 3.36. MALDI mass spectrum with insets of experimental (left) and simulated (right) envelope 
intensities for Ru(dmit)4Cl2 (8).  
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Figure 3.37. MALDI mass spectrum with insets of experimental (left) and simulated (right) envelope 
intensities for Ru (dmise)4Cl2 (9).  
 
 
Figure 3.38. Positive-ion MALDI mass spectrum with insets of experimental (left) and simulated (right) 
envelope intensities for [Ru(MMI)6]Cl3 (1a) after H2O2 addition. 
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Figure 3.39. Negative-ion MALDI mass spectrum with insets of experimental envelope intensities for 
[Ru(MMI)6]Cl3 (1a) after H2O2 addition.  
 
 
Figure 3.40. Positive-ion MALDI mass spectrum with insets of experimental (left) and simulated (right) 
envelope intensities for [Ru(dmit)6]Cl3 (2) after H2O2 addition. 
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Figure 3.41. Negative-ion MALDI mass spectrum with insets of experimental envelope intensities for 
[Ru(dmit)6]Cl3 (2) after H2O2 addition.  
 
 
Figure 3.42. Positive-ion MALDI mass spectrum with insets of experimental (left) and simulated (right) 
envelope intensities for [Ru(dmise)6]Cl3 (3) after H2O2 addition. 
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Figure 3.43. Negative-ion MALDI mass spectrum with insets of experimental envelope intensities for 
[Ru(dmise)6]Cl3 (3) after H2O2 addition. 
 
 
 
Figure 3.44. UV-vis spectra of A) [Ru(dmit)6]Cl3 and B) [Ru(dmise)6]Cl3 (100 μM) in acetonitrile before 
and after addition of 2 and 12equiv H2O2. 
 
 
 
 
 
 
A 
B 
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Figure 3.45.  Kinetics curves for [Ru(dmit)6]Cl3 upon treatment with A) 2 equiv and 12 equiv H2O2, (0-8000 
s) and B) the best-fit line fit to the initial linear portion of the kinetic curves with 2 equiv and 12 equiv H2O2 
(0-2000 s; R2 = 0.996 and 0.999, respectively). 
 
 
 
Figure 3.46.  Kinetics curves for [Ru(dmise)6]Cl3 upon treatment with A) 2 equiv and 12 equiv H2O2, (0-
8000 s) and B) the best-fit line fit to the initial linear portion of the kinetic curves with 2 equiv and 12 equiv 
H2O2 (0-100 s; R2 = 0.994 and 0.995, respectively). 
 
Table 3.7. Gel electrophoresis results for DNA damage prevention assays with [Ru(MMI)6]Cl3 (1).a 
Gel lane 
[1] 
(μM) 
% Supercoiled % Nicked 
% Damage 
Inhibition 
p Value 
1: plasmid DNA (p) 0 99.93 ± 0.12 0.07 - - 
2: p + H2O2 (50 µM) 0 99.31 ± 1.20 0.69 - - 
3: p + [Ru(MMI)6]Cl3 (1) + H2O2 1000 98.91 ± 1.39 1.09 - - 
4: p + FeII (2 µM) + H2O2 0 13.62 ± 4.33 86.38 - - 
5: p + FeII + H2O2 + 1 0.001 12.70 ± 1.00 87.30 -0.30 ± 1.01 0.658 
6: 0.01 17.06 ± 7.73 82.94 4.79 ± 7.72 0.395 
7: 0.1 13.05 ± 3.26 86.95 0.16 ± 3.25 0.940 
8: 1 39.31 ± 0.35 60.69 30.57 ± 0.35 >0.001 
9: 10 93.18 ± 0.99 6.82 92.89 ± 1.00 >0.001 
10: 50 99.61 ± 0.58 0.39 100.34 ±0.61 >0.001 
11: 100 100.00 ± 0 0.00 100.80 ± 0 >0.001 
12: 500 100.00 ± 0 0.00 100.80 ± 0 >0.001 
13: 1000 100.00 ± 0 0.00 100.80 ± 0 >0.001 
aData are reported as the average of three trials with calculated standard deviations shown. 
 
A B 
 A B 
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CHAPTER FOUR 
SYNTHESIS OF NOVEL RUTHENIUM NITROSYL THIONE AND SELONE 
COMPLEXES USING A NITRATE SALT 
 
4.1. Introduction 
 Nitric oxide (NO) is a vital molecule in living systems due to its multiple biological 
functions,1-4 including control of sleep and body temperature,5-6 regulation of blood 
pressure,6-7 cardiovascular control, neurotransmission,7-10 modulation of the immune and 
endocrine response, and induction of apoptosis.11-12 Biological NO is generated by nitric 
oxide synthase (NOS), an enzyme that converts L-arginine to L-citrulline and NO.13 The 
short lifetime and instability of NO makes the study of its physiological roles difficult;1 
therefore, many studies have used transition metal complexation as a way to obtain stable 
nitrosyl compounds.14-15 In addition, NO delivery by metal-nitrosyl complexes can release 
NO to biological targets directly while avoiding effects on untargeted cells, and ruthenium-
nitrosyl complexes have been synthesized for this purpose.16 
 Ruthenium complexes have high affinity for NO, solubility in water, accessibility 
of different oxidation states under physiological conditions, thermodynamic stability, low 
toxicity, and photolability; therefore, ruthenium nitrosyl complexes are some of the most 
investigated compounds for biological NO delivery.1,17-23 For example, the nitrosyl ligand 
in the complex trans-[(Ru(NH3)4L(NO)]3+ (L = pyridine, 4-methyl-pyridine) can be 
released in aqueous solution upon UV irradiation (300-370 nm) to form                               
trans-[(Ru(NH3)4L(H2O)]3+.23 
 In addition to NO delivery agents, ruthenium complexes have been synthesized as 
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biological NO scavengers.18,24-27 NO scavenging can control nitric oxide bioavailability 
and modulate homeostatic vascular function that is regulated by NO release.28 The nitrosyl 
complex [Ru(NO)(dha-tsc)Cl(H2O)] (dhs-tsc = N-dehydroacetic acid-thiosemicarbazide) 
was examined for its antibacterial properties as a potential treatment for  urinary tract 
infections.29 
 In addition to nitrosyl complexes of ruthenium, complexes with thione and selone 
ligands are also of interest as models for the reactivity of biological thiones and selones 
such as ergothioneine,30-37 selenoneine,38 and methimazole.39-40 In recent years, thione 
ruthenium complexes have attracted attention due to their potential antimicrobial and 
antitumor applications.41-44 Despite a variety of potential applications, however, synthesis 
of metal-nitrosyl complexes can be difficult, requiring toxic NO gas or unstable nitrosyl 
salts to add this ligand. 
 In this work, we report the synthesis and characterization of Ru(II)-nitrosyl 
complexes with N,N’-dimethylimdiazole -thione (dmit) or N,N’-dimethylimdiazole -selone 
(dmise) ligands from RuCl3∙xH2O and silver nitrate as a simple and convenient nitrosyl 
source. This synthetic procedure avoids complicated syntheses of nitrosyl complexes with 
low yields and the use of toxic or unstable reagents for NO addition. This method will 
greatly facilitate synthesis of ruthenium-nitrosyl complexes, a class of widely studied, 
potentially bioactive compounds. 
 
4.2. Results and Discussion 
 Synthesis of Ru(II)-nitrosyl complexes.  Novel Ru(II)-nitrosyl complexes with 
119 
 
thione or selone ligands were synthesized using a two-step process.  In the first step, a 
solution of RuCl3∙xH2O in acetonitrile was treated with AgNO3 (2 equiv) under argon, and 
the reaction mixture was heated to reflux for 4 h (Scheme 4.1). During this time, the dark 
reaction mixture became pale, indicating Ru(III) reduction to Ru(II). After filtration of the 
AgCl precipitate, an acetonitrile solution of dmit or dmise (4 equiv) was added to the 
filtrate.  The reaction mixture was then heated to reflux for 4 h and cooled before adding 
NaBF4 (2 equiv) and heating the reaction mixture to reflux for an additional 8 h. After 
purification, [Ru(NO)(dmit)4Cl][BF4]2  (1) and [Ru(NO)(dmise)4Cl][BF4]2 (2) were 
obtained in  good yield as brown and purple solids, respectively (Scheme 4.1). Both Ru-
nitrosyl complexes are soluble in and stable to water and air as solids and stable in solution 
for at least 24 h. 
reflux 4 h
RuCl3.3H2O
Step 1
1. 4L , reflux 4 h3 AgNO3
 +  2 AgCl 2. 3 NaBF4
     reflux 8 h
[RuL4(NO)Cl][BF4]2
Step 2
1  L = dmit (65 %)
2  L = dmise (67 %)
[Ru(NCCH3)4(NO)Cl][NO3]2 + Ag(s)
Scheme 4.1. Method for forming Ru(II) complexes 1 and 2 in acetonitrile. 
 
 The identities of complexes 1 and 2 are supported by mass spectrometry data that 
show [Ru(NO)(dmit)3(BF4)2]+  (m/z =  690) and [Ru(NO)(dmit)4Cl(BF4)]+ (m/z = 766) ions 
for 1, and [Ru(NO)(dmise)2(BF4)2]+ (m/z = 655) and [Ru(NO)(dmise)2Cl(BF4)2H]+ (m/z =  
692) ions for 2 (Figures 4.3-4.4). The product formed prior to dmit or dmise addition, was 
also characterized by mass spectrometry as the Ru(II)-NO complex 
[Ru(NO)(NCCH3)4Cl(NO3)]+ (m/z = 392; Figure 4.5), indicating that Ru(III) reduction and 
NO formation occur in step 1. A small amount of silver mirror formed on the bottom of the 
reaction flask, indicating Ag+ reduction to Ag0, and the Ag+/Ag0 redox potential (0.80 V) 
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and Ru3+/Ru2+ redox potential (0.25 V)45 support electrochemical reduction of Ru3+ to Ru2+ 
and Ag+ to Ag0 by electrons released from thermal decomposition of NO3 to NO and O2.46-
47 No Ru-NO product is observed as a product of the step 1 reaction unless the reaction 
mixture is heated.  Thus, step 2 replaces the labile acetonitrile ligands with thione and 
selone ligands and exchanges the counterions. Interestingly, products 1 and 2 also form in 
very low yields when NaNO3 is used in place of AgNO3, so it is likely the presence of Ag+ 
facilitates this reaction.  To the best of our knowledge, this is the first report of Ru-NO 
complexes synthesized using a nitrate salt, although NO has been reported as a thermal 
decomposition product of metal nitrates.47  The use of a nitrate salt in place of typical NO 
addition reagents greatly simplifies generation of Ru-NO complexes. 
       Structural analysis of Ru(II)-nitrosyl complexes. Complexes 1 and 2 were 
characterized by X-ray structural analysis from single crystals grown by slow diffusion of 
diethyl ether into acetonitrile solutions of the complexes. Both complexes crystalize in 
space group P21/c, although they are not isomorphous. Ru(II) centers in 1 and 2 adopt 
distorted octahedral geometry, with S1-Ru1-S2 bond angles of 89.38(4) and 90.62(4)º in 1 
and Se1-Ru1-Se2 bond angles of 89.690(16)-90.311(16) in 2 (Figure 4.1 and Tables 4.1, 
4.5, and 4.6). The four dmit/dmise ligands in the equatorial plane are coordinated through 
the S/Se atoms, with the nitrosyl and chloride ligands trans to each other in the axial 
positions to complete the coordination sphere.  In both complexes, the NO and Cl ligands 
are disordered with one another over both of the axial positions, as often occurs in such 
complexes.  The Ru-S bond lengths in 1 are 2.426(10) and 2.4349(10) Å, similar to Ru-S 
bond lengths of other Ru(II)-thione complexes are such as in [RuCl (L1)2CO(PPh3)2] (L1 = 
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1-(4-methyl-phenyl)-imidazole-2-thione) 2.478(2) Å,48 and  [Ru(L2)2(PPh3)2Cl2] (L2 = 1-
(4-chlorophenyl)imidazole-2-thione)  2.4087(16) Å .49  For 2, the Ru-Se bonds lengths are 
slightly longer (2.5422(5) and 2.5452(5) Å), similar to Ru-Se bond lengths in [(η6-
C6H6)Ru(L3)Cl][PF6](L3 = 1-benzyl-3-phenylselenylmethyl- 
1,3-dihydrobenzoimidazole-2-selone) (2.5431(10) and 2.5434(9) Å.50 
 
 
 
Figure 4.1. Crystal structure diagrams of A) [Ru(NO)(dmit)4Cl](BF4)2 (1) and B) 
Ru(NO)(dmise)4Cl](BF4)2 (2) showing 50% ellipsoids; hydrogen atoms and counterions are omitted for 
clarity. 
 
The C-S bond lengths in 1 are 1.714(4) and 1.718(4) Å, longer than in unbound dmit (1.696 
Å51), this elongation is due to increased contribution from the zwitterionic resonance 
structure upon metal binding, a trend that has been observed previously.52-54 The range of 
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N-C bond lengths of 1.343(6)-1.377(6) in the dmit ligands in 1 is not significantly different 
from the N-C bond lengths in unbound dmit (1.349(6) Å51). Similarly, the C-Se bond 
lengths in 2 are 1.865(5) and 1.868(4) Å, and also slightly longer than those for unbound 
dmise 1.843(4) Å.55 Similarly, the C-N bond lengths for the dmise ligands in 2 are not 
significantly different from those of unbound dmise (1.334(7) and 1.343(6) Å, 
respectively).55 
 
Table 4.1. Selected bond lengths (Å) and angles (deg) for [Ru(NO)(dmit)4Cl](BF4)2  (1) and 
[Ru(NO)(dmise)4Cl](BF4)2 (2). 
     1           2 
Ru1-N5 1.69(2) 1.679(13) 
Ru1-E1 2.4259(10) 2.5422(5) 
Ru1-E2 2.4349(10) 2.5452(5) 
E1-C1 1.714(4) 1.865(5) 
N-O 1.31(2) 1.23(18) 
N5-Ru1-E1 89.1(11) 90.4(8) 
N5-Ru1-E1 90.9(11) 89.7(8) 
E1-Ru1-E1 180.00(6) 180.0 
Cl5-Ru1-E2 90.7(2) 93.06(14) 
O-N-Ru 174(3) 169(3) 
 
 
         In both complexes, the coordinated NO ligand is nearly linear, with Ru-N-O angles 
of 174(3) and 169(3)º for 1 and 2, respectively. This indicates a formal NO+ ligand, 
consistent with the range of Ru-N-O angles (164-178º) for reported Ru-NO complexes with  
linear binding modes.58-59,61,64  The N-O bond length in 1 (1.31(2) Å) is longer than that of 
2  (1.234(18) Å; Table 4.5), indicating the possibility of greater Ru(II)-NO backbonding in 
dmit complex 1. For both complexes, the N-O bond length is longer than the N-O bond 
lengths for reported Ru(II)-nitrosyl complexes (1.14-1.25 Å),14-15,56-69 and the Ru-N 
distances in 1 and 2 (1.69 (2) and 1.679(13) Å, respectively) are slightly shorter than those 
in reported nitrosyl ruthenium complexes (1.72-1.79 Å).14-15,55-69  These effects may be due 
123 
 
to the NO/Cl disorder present in the structures.  These complexes represent, to our 
knowledge, the first reported Ru-nitrosyl compounds with imidazole -thione or -selone.  
 Infrared and NMR spectroscopy. IR spectra of [Ru(NO)(dmit)4Cl][BF4]2  (1) and 
[Ru(NO)(dmise)4Cl][BF4]2 (2) show NO stretching bands of the nitrosyl ligands at 1827 
and 1810 cm-1, respectively (Table 4.2; Figures 4.6, 4.7, and 4.10).  The presence of these 
bands in the 1700-1920 cm-1 range are diagnostic of a formally NO+ ligand bound to 
Ru(II),70 consistent with linear NO binding as observed in the structures of 1 and 2.63,70 
Relative to unbound NO (1870 cm-1 71), bands at 1829 and 1810 cm-1 for 1 and 2, 
respectively, indicating that the Ru-bound NO ligand is less reactive than free NO. The 
range for NO+ stretching bands in [Ru(NO)(R-Phtpy)Cl2]+ (R-Phtpy = 4′-position of 
terpyridine ligands) and  [Ru(NO)(NH3)3Cl2]Cl is 1880-1930 cm-1,59,64 higher than observed 
for 1 and 2, likely indicating that dmit and dmise binding decreases the NO stretching 
frequency relative to nitrogen donor ligands.  
Table 4.2. Selected IR stretches and NMR resonances (in D2O) for compounds 1 and 2. 
 
Compound  
 
IR (cm-1) 
       S/Se=C           N≡O  
1H NMR shifts (δ) 
     CH3            C-H 
Dmit       118171      - 3.48 6.95 
Dmise   114772 - 3.61 7.16 
[Ru(NO)(dmit)4Cl][BF4]2  (1) 1171 1827 3.61 7.17 
[Ru(NO)(dmise)4Cl][BF4]2  (2) 1151 1810 3.61 6.72 
 
 The C=S stretching band for 1 is observed at 1171 cm-1, slightly shifted to lower 
energy compared to unbound dmit (1181 cm-1;72 Table 4.2). In contrast, the C=Se stretch 
for 2 is observed at 1151 cm-1, not significantly shifted compared to unbound dmise     
(1147 cm-1 73).  These IR results suggest the primarily σ- and π-donor interactions of Ru(II)-
coordinated dmit and dmise ligands, with dmise having  somewhat more donor character 
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than dmit. Similar shifts in C=S/C=Se bond stretches have been observed for Cu(I),75-76 
Ni(II),77 Co(III),77-78 Fe(II),50 and Zn(II)50 complexes of dmit and dmise. 
 1H NMR spectra for 1 and 2 (Table 4.2 and Figures 4.3-4.5) show a downfield shift 
for the methyl proton resonance in dmit complex 1 (δ 3.61) compared to unbound dmit (δ 
3.48), but show no shift for the methyl resonances in dmise complex 2 (δ 3.61) relative to 
unbound dimse. This downfield shift for the methyl proton resonance of 1 is consistent 
with increasing the contribution of the aromatic resonance structure that increases the 
negative charge on the sulfur atom of the thione.51 The stronger donor character of Ru(II)-
coordinated dmise compared to dmit is also observed in a downfield shift for the olefinic 
protons (δ 7.17) in 1 compared to unbound dmit (δ 6.95), whereas the olefinic resonances 
for dmise complex 2 (δ 6.72) shift upfield relative to unbound dmise (δ 7.16). These 
opposite NMR shifts for the olefinic protons indicate less contribution of the zwitterionic 
resonance structure for dmise ligands in 2 relative to dmit ligands in 1, consistent with IR 
results.        
 To further investigate the identity of the product formed prior to dmit or dmise 
addition (Scheme 4.1), the reaction mixture was filtered after step 1 to remove the AgCl 
precipitate, and the solvent was removed in vacuo to yield a brown powder.   As mentioned 
previously, analysis of this sample by mass spectrometry indicates the presence of 
[Ru(NO)(NCCH3)4Cl(NO3)]+.  Consistent with formation of this Ru(II)-nitrosyl species, 
nitrile stretches are observed at 2300 and 2331 cm-1 in the IR spectrum of the reaction 
mixture, consistent with Ru-bound acetonitrile ligands (Figure 4.10).79 Additionally, a 
sharp NO stretching band is observed at 1894 cm-1, consistent with the species identified 
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by mass spectrometry. This NO stretch is 67 and 84 cm-1 higher than the NO stretches in 1 
and 2, respectively, likely due to the increased electron donation of dmit and dmise relative 
to acetonitrile ligands. In contrast, N-O stretching bands for coordinated nitrate ligands in 
[Ag(H2BzPh)(NO3)] (H2BzPh = 2-benzoylpyridine benzoylhydrazone) are observed at 
1384 cm-1,80 much lower frequency than bands for coordinated NO. These results further 
support the formation of NO directly from AgNO3 treatment of RuCl3⋅xH2O, prior to dmit 
or dmise addition.  Crystallization attempts of this Ru(II) nitrosyl-containing product have 
thus far proven unsuccessful.  
 Electrochemical analysis. Understanding the electronic distribution in transition 
metal-nitrosyl bonds is complex,82-84 and Ru-NO complexes have been synthesized and 
their electrochemical properties examined for this purpose.82-84 In the cyclic 
voltammograms (CV) of [Ru(NO)(dmit)4Cl][BF4]2  (1) [Ru(NO)(dmise)4Cl][BF4]2  (2), 
dmit and dmise ligand-based redox waves dominate, with (Epc) and oxidation (Epa) waves 
for Ru-bound dmit in 1 observed at 0.36 and 1.06 V, respectively (Figure 4.2 and Table 
4.3).  These waves are 0.50 and 0.58 V higher, respectively, than analogous waves 
observed for unbound dmit. For Ru-bound dmise in 2, Epc and Epa waves are seen at 0.31 
and 0.85 V,respectively, 0.46 and 0.48 V higher than for unbound dmise.51 Thus, Ru 
coordination shifts the ligand-based potentials to higher potential, indicating that both 
ligand oxidation and reduction are more spontaneous.  This effect is slightly more 
pronounced for dmit complex 1 compared to dmise complex 2, and similar trends are 
observed Fe(II)-thione complexes Fe(dmit)2Cl2, [Fe(dmit)2(CH3CN)2][BF4]2, and  
[Fe(dmit)4][OTf]2.50 
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 In the CV for dmise complex 2, smaller waves at high potentials are consistent with 
a reversible Ru(III/II) couple (E1/2 = 1.03 V; Table 4.3), which is typically observed in the 
range of 0.18 to 1.67 V.87 Ru(IV/III) reduction potentials for 
[RuIIICl3(CH3CN)L1]·L1·3H2O, (L1 = 2-(2’-pyridyl)benzimidazole) are in the range 1.05 
to 1.16 V,88  consistent with this assignment.  Similar Ru(IV/III) waves are not clearly 
observed in the CV for 1, perhaps due to overlap with the strong ligand-based waves.   
 
Figure 4.2.  A) Cyclic voltammogram (CV) for A) [Ru(dmit)4Cl(NO)][BF4]2 (1), B) CV for 
[Ru(dmise)4Cl(NO)][BF4]2 (2). Samples were prepared with 0.1 mM complex in acetonitrile with tetra-n-
butyl ammonium phosphate (0.1 M) as the supporting electrolyte. 
For both complexes 1 and 2, two additional reduction waves are observed at -0.33 and -
0.24 V for 1 and -0.46 and -0.29 V for 2 (Figure 4.10), likely corresponding to Ru(III/II) 
and NO reductions. Typical Ru(III/II) cathodic waves occur in the range 1.5 to −0.4 V88 
whereas NO-based cathodic waves occur in the -0.10 to -0.40 V range for  
A
B
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[Ru(NO)(bpy)2L]2+ (L = Cl-, N3-, NO2-) and [Ru(NO)(bpy)2L]3+ (L = NH3, NCCH3, and 
pyridine) complexes,70 at significantly lower potentials than the corresponding Ru(III/II) 
waves for these complexes. These comparisons suggest that the cathodic waves at -0.33 
and -0.46 for 1 and 2, respectively, are due to NO-based reduction waves, whereas the 
cathodic waves at -0.24 and -0.29 V are due to Ru(III/II) reduction for 1 and 2, respectively. 
If this is the case, the presence of Ru-bound dmit ligands in 1 does not significantly shift 
NO-based reduction potentials compared to the similar [Ru(NO)(bpy)2Cl]2+ complex (NO 
reduction at -0.36 V),70 but analogous dmise coordination in 2 makes NO reduction less 
favorable. Corresponding Ru(II/III oxidation waves are not clearly observed, although 
additional differential pulse voltammogram experiments may help to identify these 
oxidation waves, as well as Ru(IV/III) waves for complex 1.  The results of these 
electrochemical studies, combined with the IR and NMR characterization data indicate that 
dmit binding differs from dmise binding in these Ru(II)-nitrosyl complexes, and that dmise 
binding makes the nitrosyl ligand more nucleophilic. 
 
Table 4.3. Electrochemical data for thione and selone ligands and ruthenium complexes 1 and 2 vs. NHE. 
Ligand or Complex 
Ligand-based 
Potentials (V) Ru
IV/III-based Potentials (V) 
Epc Epa Epc Epa ΔE E1/2 
dmit  -0.14 0.59 - - - - 
dmise  -0.15    0.37 - - - - 
[Ru(NO)(dmit)4Cl]2+ (1) 0.36    1.06 - - - - 
[Ru(NO)(dmise)4Cl]2+ (2) 0.31 0.85 0.97 1.08 0.11 1.03 
 
 
4.3. Conclusions 
 Overall, this work reports the synthesis and characterization of two novel Ru(II)-
nitrosyl complexes with thione and selone ligands.  Their synthesis is notable because the 
128 
 
nitrosyl ligand is derived from a metal nitrate salt, a much easier method than using typical 
NO-addition reagents. This method allows a simple entry point into Ru-NO chemistry, and 
further investigations will determine whether this reaction method can be extended to form 
NO complexes with other d-block metal ions. This work greatly facilitates synthesis of Ru-
nitrosyl complexes and may contribute to enhancing and developing their applications. 
  
4.4. Experimental methods 
 General methods. Synthesis of all complexes was performed under argon using 
standard air-sensitive Schlenk techniques except where indicated. Ru(III) chloride hydrate 
(Oakwood), silver nitrate (BDH) , and sodium nitrate (BDH) were used without 
purification. 1,3-Dimethyl-2(3H)-imidazolethione (dimt) and 1,3-dimethyl-2(3H)-
imidazoleselone(dimse) were synthesized as reported by Roy et al.40 Acetonitrile was 
purified by distillation under an argon atmosphere, and anhydrous diethyl ether (BDH) was 
used without further purification.  
 1H NMR spectra were recorded using a 300 MHz Bruker-AVANCE NMR 
spectrometer; 1H NMR chemical shifts are reported in δ relative to tetramethylsilane (δ 0) 
and referenced to solvent (1H NMR spectra of 1 and 2 in D2O are shown in Figures 4.2-
4.3).   IR spectra were obtained from Nujol mulls on KBr salt plates with a Magna 550 IR 
spectrometer (Figures 4.4-4.6). Vibrational data are described using the abbreviations: vs, 
very strong; s, strong; m, medium; w, weak; b, broad. MALDI mass spectra were obtained 
using a Bruker Microflex MALDI-TOF mass spectrometer with trans-2-[3-(4-tert-
butylphenyl)-2-methyl-2-propenyldiene] malonitrile (m/z 251.3 for cation with H+) as the 
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matrix. All observed peak envelopes match theoretical calculations89 for their ions (Figures 
4.7-4.9).  
    Synthesis of [Ru(NO)(dmit)4Cl][BF4]2 (1). RuCl3·3H2O (261 mg, 1 mmol) was 
dissolved in acetonitrile and AgNO3 (3 mmol, 510 mg) was added to the solution. The 
reaction mixture was stirred and heated to reflux for 4 h under argon, then filtered to 
remove the AgCl precipitate. Dmit (4 mmol, 513 mg) dissolved in dichloromethane (15 
mL) was added to the filtrate, and the reaction mixture was stirred and heated to reflux for 
an additional 4 h. Upon cooling, NaBF4 (3 mmol, 330 mg) was added to the reaction 
mixture, and it was again stirred and heated to reflux for 8 h, during which time a white 
precipitate formed.  The reaction mixture was cooled and filtered to remove the precipitate, 
and the solvent was removed in vacuo. The resulting brown powder was washed with 
diethyl ether (2 × 20 mL) and dissolved in acetonitrile (25 mL).  The resulting mixture was 
filtered and recrystallized by vapor diffusion of diethyl ether into the acetonitrile solution 
at room temperature. After 6-12 h, crystals of [Ru(NCCH3)6][BF4]2 were filtered, and the 
resulting filtrate was again crystallized from vapor diffusion of diethyl ether to afford 1 as 
a brown, microcrystalline solid. Yield: 554 mg, 65%. Crystals for X-ray analysis were 
grown from vapor diffusion of diethyl ether into a solution of 1 in acetonitrile. IR (Nujol, 
cm-1): 3404 (b), 3148 (w), 2926 (s), 2856 (s),  2727 (w), 1827 (w), 1662 (m), 1562 (m), 
1460 (s), 1378 (s), 1304 (w), 1172 (s), 1083 (s), 1044 (w),  851 (w), 723 (s) ), 647 (w), 520 
(w). Analysis of C20H32ClB2F8N9RuS4·2CH3CN·3H2O, Calcd. (Exp.): C, 28.58 (28.82); H, 
4.56 (4.63); N, 15.21 (14.82). MALDI-MS m/z = 690, [Ru(NO)(dmit)3(BF4)2]+  and 766, 
[Ru(NO)(dmit)4Cl(BF4)]+. Complex 1 was synthesized also using the same procedure as 
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described above except that NaNO3 (3 mmol, 245 mg) was added in place of AgNO3, yield 
7%. 
 Synthesis of [Ru(NO)(dmit)4Cl][BF4]2 (2). Synthesis of 2 was carried out using the 
same procedure as described for 1 except that dmise (4 mmol, 700 mg) was added in place 
of dmit. The resulting purple powder was purified as described for 1, affording product 2 
as a purple, microcrystalline solid. Crystals for X-ray analysis were grown from vapor 
diffusion of diethyl ether into a solution of 2in acetonitrile. Yield: 697 mg, 67 %. IR (Nujol, 
cm-1): 3399 (b), 3174 (w) 2925 (s), 2831 (s),  2728 (w), 1810 (w), 1661 (w), 1566 (m), 
1456 (s), 1379 (s), 1238 (w), 1151 (s), 1077 (s), 1042 (s), 966 (m), 851 (w), 723 (s), 651 
(w), 519(w), 468 (w). Analysis of C20H32ClB2F8N9RuSe4·CH3CN): Calcd. (Exp.): C, 24.39 
(24.87); H, 3.23 (3.23); N, 12.93 (12.90). MALDI-MS m/z = 655, 
[Ru(NO)(dmise)2(BF4)2]+ and 692, [Ru(NO)(dmise)2Cl(BF4)2H]+. Complex 2 was 
synthesized also using the same procedure as described above except that NaNO3 (3 mmol, 
245 mg) was added in place of AgNO3, yield 10%. 
 Electrochemistry. Cyclic voltammogram and differential pulse voltammetry (DPV) 
measurements for complexes 1 and 2 were obtained using a CH Electrochemical Analyzer 
(CH Instruments, Inc.) with a glassy carbon working electrode, Ag/AgCl reference 
electrode, and a Pt counter-electrode in a compartment cell. Tetra-n-butyl ammonium 
phosphate (0.1 M) was used as the supporting electrolyte in acetonitrile (distilled under 
argon and stored over 4 Å molecular sieves) with a 0.1 mM concentration for complexes 1 
and 2.  Samples were deaerated for 10 minutes by vigorous nitrogen purge. CV studies 
were conducted at a scan rate of 100 mV/s. All measured redox potentials were adjusted to 
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NHE (0.198 V83) from Ag/AgCl, and referenced to the ferrocenium/ferrocene couple 
(0.400 V vs. NHE84). 
 X-ray crystallography. Complexes 1 and 2 were characterized by X-ray structural 
analysis. Single crystals of 1 and 2 were grown via slow diffusion of diethyl ether into 
acetonitrile solutions. Diffraction data were collected using a Bruker D8 Venture 
diffractometer with a Mo Kα (λ = 0.71073 Å) microfocus source and a Photon 100 CMOS 
detector. Data were collected by phi and omega scans, and processed and corrected for 
absorption using the Apex 3 software suite.  The structures were solved and refined by full-
matrix least squares techniques on F2 using the SHELXTL software suite.  Crystallographic 
data for complexes 1 and 2 is shown in Table 5. 
 
Table 4.4. Crystallographic data for [RuCl(NO)(dmit)4](BF4)2 (1) and [RuCl(NO)(dmise)4](BF4)2 (2). 
                   1                      2 
Empirical formula C20H32B2ClF8N9ORuS4  C20H32B2ClF8N9ORuSe4 
Formula weight (g/mol) 852.92 1040.52 g/mol 
Temperature (K) 140(2) K 140(2) K 
Crystal system monoclinic  monoclinic  
Space group P21/c P21/c 
Unit cell dimensions (Å,°) 
a = 8.3673(6)Å 
b = 19.5553(12) Å  
c = 10.5028(7) Å  
β = 98.257(2) ° 
a = 10.6266(5) Å 
b = 10.3586(5) Å  
c = 16.1181(8) Å 
β = 95.229(2) ° 
Volume (Å3) 1700.7(2) 1766.84(15) 
Z, calcd density (g/cm3) 2 2 
Absorption coefficient (mm-1) 0.862 4.714 
F(000) 860 1004 
Crystal size (mm) 0.038 × 0.087 × 0.301 0.032 × 0.187 × 0.214 
Tmax, Tmin 0.9680 and 0.7810 1.0000 and 0.7553 
Θ range for data 2.67 to 25.50° 2.75 to 26.43° 
Reflns collected/unique/obs. 41562 34262 
Data/restraints/parameters 3160 / 36 / 256 3622 / 19 / 237 
Goodness-of-fit on F2 1.262 1.062 
R1, wR2 (I ≥ 2σ(I)) R1 = 0.0517, wR2 = 0.0974 R1 = 0.0421, wR2 = 0.1030 
R1, wR2 (all data) R1 = 0.0604, wR2 = 0.1001 R1 = 0.0581, wR2 = 0.1123 
Largest diff.  peak, hole (e/Å3) 0.427 and -0.842 0.787 and -0.766 
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4.5 Supplemental Material 
 
 
 
Figure 4.3. MALDI mass spectrum with insets of experimental (left) and simulated (right) envelope 
intensities for [Ru(NO)(dmit)4Cl][BF4]2 (1). 
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Figure 4.4. MALDI mass spectrum with insets of experimental (left) and simulated (right) envelope 
intensities for [Ru(NO)(dmise)4Cl][BF4]2 (2). 
 
 
 
Figure 4.5. MALDI mass spectrum with insets of experimental (left) and simulated (right) envelope 
intensities for the reaction mixture prior to addition of dmit or dmise. 
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Table 4.5. Selected interatomic distances and angles for [Ru(NO)(dmit)4Cl][BF4]2 (1).   
Bond lengths (Å)  Bond angles (°)  
Ru1-N5 1.69(2) Ru1-Cl5 2.263(6) 
Ru1-S1 2.4259(10) Ru1-S1 2.4260(10) 
Ru1-S2 2.4349(10) Ru1-S2 2.4350(10) 
S1-C1 1.714(4) S2-C6 1.718(4) 
N5-O5 1.31(2) N1-C1 1.344(6) 
N1-C2 1.384(7) N1-C4 1.454(7) 
N2-C1 1.341(6) N2-C3 1.392(7) 
N2-C5 1.446(8) N3-C6 1.343(6) 
N3-C7 1.377(7) N3-C9 1.455(7) 
N4-C6 1.351(6) N4-C8 1.377(6) 
N4-C10 1.450(7) C2-C3 1.307(9) 
C2-H2 0.95 C3-H3 0.95 
C4-H4A 0.98 C4-H4B 0.98 
N5-Ru1-S1 89.1(11) Cl5-Ru1-S1 90.1(2) 
N5-Ru1-S1 90.9(11) Cl5-Ru1-S1 89.9(2) 
S1-Ru1-S1 180.00(6) N5-Ru1-S2 90.4(11) 
Cl5-Ru1-S2 90.7(2) S1-Ru1-S2 89.38(4) 
S1-Ru1-S2 90.62(4) N5-Ru1-S2 89.6(11) 
Cl5-Ru1-S2 89.3(2) S1-Ru1-S2 90.62(4) 
S1-Ru1-S2 89.38(4) S2-Ru1-S2 180.0 
C1-S1-Ru1 108.56(14) C6-S2-Ru1 106.40(15) 
O5-N5-Ru1 174.(3) C1-N1-C2 108.5(5) 
C1-N1-C4 125.6(4) C2-N1-C4 125.9(5) 
C1-N2-C3 108.3(5) C1-N2-C5 124.8(5) 
C3-N2-C5 126.9(5) C6-N3-C7 108.9(5) 
C6-N3-C9 125.3(4) C7-N3-C9 125.7(5) 
 
 
 
Table 4.6. Selected interatomic distances (Å) and angles (°) for [Ru(NO)(dmise)4Cl][BF4]2 (2). 
Bond lengths (Å)  Bond angles (°)  
Ru1-N5 1.679(13) Ru1-Cl5 2.437(11) 
Ru1-Se1 2.5422(5) Ru1-Se1 2.5422(5) 
Ru1-Se2 2.5452(5) Ru1-Se2 2.5453(5) 
Se1-C1 1.865(5) Se2-C6 1.868(4) 
N5-O5 1.234(18) N1-C1 1.350(7) 
N1-C3 1.364(8) N1-C4 1.444(9) 
N2-C1 1.350(7) N2-C2 1.386(8) 
N2-C5 1.460(10) N3-C6 1.362(7) 
N3-C7 1.365(7) N3-C9 1.463(8) 
N4-C6 1.333(6) N4-C8 1.371(6) 
N4-C10 1.455(7) C2-C3 1.337(11) 
N5-Ru1-Se1 90.4(8) Cl5-Ru1-Se1 88.31(14) 
N5-Ru1-Se1 89.7(8) Cl5-Ru1-Se1 91.69(14) 
Se1-Ru1-Se1 180.0 N5-Ru1-Se2 90.8(8) 
Cl5-Ru1-Se2 93.06(14) Se1-Ru1-Se2 89.689(16) 
Se1-Ru1-Se2 90.311(16) N5-Ru1-Se2 89.2(8) 
Cl5-Ru1-Se2 86.94(14) Se1-Ru1-Se2 90.310(16) 
Se1-Ru1-Se2 89.690(16) Se2-Ru1-Se2 180.0 
C1-Se1-Ru1 104.83(13) C6-Se2-Ru1 105.65(13) 
O5-N5-Ru1 169.(3) C1-N1-C3 109.4(6) 
C1-N1-C4 125.5(5) C3-N1-C4 125.1(6) 
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Figure 4.6. Transmittance IR spectrum of [Ru(NO)(dmit)4Cl][BF4]2 (1) acquired as a Nujol mull. 
 
 
 
 
Figure 4.7. Transmittance IR spectrum of [Ru (NO)(dmise)4Cl][BF4]2 (2) acquired as a Nujol mull. 
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Figure 4.8. 1H NMR spectrum of [Ru(NO)(dmit)4Cl][BF4]2 (1) in D2O (δ 4.79). 
 
 
Figure 4.9. 1H NMR spectrum of [Ru(NO)(dmise)4Cl][BF4]2 (2) in D2O (δ 4.79). 
 
 
Figure 4.10. IR spectrum of reaction mixture prior to dmit or dmise addition acquired as a Nujol mull. 
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